<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5329042</article-id><article-id pub-id-type="doi">10.3389/fimmu.2017.00191</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>A Potential Role of <italic>Salmonella</italic> Infection in the Onset of Inflammatory Bowel Diseases</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Schultz</surname><given-names>B&#x000e1;rbara M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Paduro</surname><given-names>Carolina A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Salazar</surname><given-names>Geraldyne A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/237575"/></contrib><contrib contrib-type="author"><name><surname>Salazar-Echegarai</surname><given-names>Francisco J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/237618"/></contrib><contrib contrib-type="author"><name><surname>Sebasti&#x000e1;n</surname><given-names>Valentina P.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Riedel</surname><given-names>Claudia A.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kalergis</surname><given-names>Alexis M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/217683"/></contrib><contrib contrib-type="author"><name><surname>Alvarez-Lobos</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/390612"/></contrib><contrib contrib-type="author"><name><surname>Bueno</surname><given-names>Susan M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/383267"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Facultad de Ciencias Biol&#x000f3;gicas, Departamento de Gen&#x000e9;tica Molecular y Microbiolog&#x000ed;a, Millennium Institute on Immunology and Immunotherapy, Pontificia Universidad Cat&#x000f3;lica de Chile</institution>, <addr-line>Santiago</addr-line>, <country>Chile</country></aff><aff id="aff2"><sup>2</sup><institution>Facultad de Ciencias Biol&#x000f3;gicas y Facultad de Medicina, Departamento de Ciencias Biol&#x000f3;gicas, Millennium Institute on Immunology and Immunotherapy, Universidad Andr&#x000e9;s Bello</institution>, <addr-line>Santiago</addr-line>, <country>Chile</country></aff><aff id="aff3"><sup>3</sup><institution>Facultad de Medicina, Departamento de Endocrinolog&#x000ed;a, Pontificia Universidad Cat&#x000f3;lica de Chile</institution>, <addr-line>Santiago</addr-line>, <country>Chile</country></aff><aff id="aff4"><sup>4</sup><institution>INSERM, UMR 1064</institution>, <addr-line>Nantes</addr-line>, <country>France</country></aff><aff id="aff5"><sup>5</sup><institution>Facultad de Medicina, Departamento de Gastroenterolog&#x000ed;a, Pontificia Universidad Cat&#x000f3;lica de Chile</institution>, <addr-line>Santiago</addr-line>, <country>Chile</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Eric Cox, Ghent University, Belgium</p></fn><fn fn-type="edited-by"><p>Reviewed by: Benjamin P. Willing, University of Alberta, Canada; Atte Von Wright, University of Eastern Finland, Finland</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Susan M. Bueno, <email>sbueno@bio.puc.cl</email>; Manuel Alvarez-Lobos, <email>manalvarez@gmail.com</email></corresp><fn fn-type="other" id="fn002"><p>Specialty section: This article was submitted to Mucosal Immunity, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>28</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>8</volume><elocation-id>191</elocation-id><history><date date-type="received"><day>15</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>09</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Schultz, Paduro, Salazar, Salazar-Echegarai, Sebasti&#x000e1;n, Riedel, Kalergis, Alvarez-Lobos and Bueno.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Schultz, Paduro, Salazar, Salazar-Echegarai, Sebasti&#x000e1;n, Riedel, Kalergis, Alvarez-Lobos and Bueno</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Inflammatory bowel disease (IBD) includes a set of pathologies that result from a deregulated immune response that may affect any portion of the gastrointestinal tract. The most prevalent and defined forms of IBD are Crohn&#x02019;s disease and ulcerative colitis. Although the etiology of IBD is not well defined, it has been suggested that environmental and genetic factors contribute to disease development and that the interaction between these two factors can trigger the pathology. Diet, medication use, vitamin D status, smoking, and bacterial infections have been proposed to influence or contribute to the onset or development of the disease in susceptible individuals. The infection with pathogenic bacteria is a key factor that can influence the development and severity of this disease. Here, we present a comprehensive review of studies performed in human and mice susceptible to IBD, which supports the notion that infection with bacterial pathogens, such as <italic>Salmonella</italic>, could promote the onset of IBD due to permanent changes in the intestinal microbiota, disruption of the epithelial barrier and alterations of the intestinal immune response after infection.</p></abstract><kwd-group><kwd>inflammatory bowel disease</kwd><kwd>Crohn&#x02019;s disease</kwd><kwd>ulcerative colitis</kwd><kwd>gut microbiota</kwd><kwd><italic>Salmonella enterica</italic> serovar Typhimurium</kwd><kwd>innate immune response</kwd><kwd>virulence factors</kwd></kwd-group><counts><fig-count count="2"/><table-count count="0"/><equation-count count="0"/><ref-count count="129"/><page-count count="12"/><word-count count="11309"/></counts></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>Inflammatory bowel disease (IBD) is defined as a set of pathologies that exhibit a progressive and chronic phenotype, where the intestinal immune response and the normal gut microbiota are altered (<xref rid="B1" ref-type="bibr">1</xref>). IBD usually begins in adolescence and persists lifelong (<xref rid="B2" ref-type="bibr">2</xref>). The symptoms of these inflammatory disease are not only limited to the gastrointestinal level but also produces systemic complications such as fever, weight loss, delayed sexual maturation and growth, among others. Further, extraintestinal diseases can be associated with IBD, including arthritis (<xref rid="B3" ref-type="bibr">3</xref>). The most common clinical manifestations of IBD are Crohn&#x02019;s disease (CD) and ulcerative colitis (UC) (<xref rid="B2" ref-type="bibr">2</xref>). CD, a manifestation that affects females in a greater proportion, is characterized by a chronic and transmural inflammation, specifically at the colon and small intestine. However, inflammatory lesion during CD can be found at any section of the gastrointestinal tract, from the mouth to the anus (<xref rid="B4" ref-type="bibr">4</xref>). These lesions can affect all layers of the gastrointestinal tract, producing strictures and fistulae (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). CD mostly affects the young population, with a peak of incidence in the early adulthood (between 20 and 30&#x02009;years old). UC, on the other hand, is a manifestation more common in males and only affects the superficial layer of the colon, with a continuous inflammation comprising from the rectus to variable distances along the intestine (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). The incidence of IBD is higher in industrialized or westernized regions, such as the United States and Northern and Western Europe, and it is mild in South America and Africa (<xref rid="B8" ref-type="bibr">8</xref>). The same pattern is observed in urban and rural areas, indicating that industrialization can be considered as an etiological factor for major incidence of IBD (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). Additional factors, such as environmental and genetic factors, interact to determine the onset and development of disease.</p><p>Different studies have shown the correlation between environmental and genetic factors that could lead to a dysfunction of the intestinal epithelial barrier, with a consequent deregulation in the function of the mucosal immune cells. These alterations lead either to an inappropriate recognition of the gut microbiota or an increased susceptibility to infections (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B9" ref-type="bibr">9</xref>). Moreover, environmental factors can differentially affect predisposition of individuals, by increasing their susceptibility to develop IBD (<xref rid="B10" ref-type="bibr">10</xref>). The increase in the incidence of IBD has been associated with several factors common to modern lifestyle, such as use of antibiotics, vaccines, contraceptives, vitamin D status, and better hygiene. Further, changes associated with westernization, such as high consumption of fats, refined sugar, and carbohydrates, have also been implicated in the incidence increase for these diseases during the last decades (<xref rid="B11" ref-type="bibr">11</xref>). According to previously observed associations between the consumption of some food and incidence of UC or CD, it is presumed that the diet could induce changes in the microbiota composition and in the cellular adhesion to the intestinal barrier (<xref rid="B12" ref-type="bibr">12</xref>), which could in turn lead the development of IBD (<xref rid="B11" ref-type="bibr">11</xref>).</p><p>Inflammatory bowel disease is a disease highly influenced by genetic factors. Several genetic mutations and polymorphism have been described in both UC and CD (<xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B15" ref-type="bibr">15</xref>). Interestingly, some of the polymorphisms associated with IBD locate in genes encoding proteins involved in bacteria recognition, degradation, or translocation through the intestinal epithelial barrier. For instance, it has been described that in both UC and CD patients there are polymorphisms in genes associated with the <italic>Th1/Th17 pathway</italic> [<italic>il23r</italic> (<xref rid="B16" ref-type="bibr">16</xref>), <italic>il12b</italic> (<xref rid="B17" ref-type="bibr">17</xref>), or <italic>stat3</italic> (<xref rid="B17" ref-type="bibr">17</xref>) genes]; <italic>autophagy</italic> [<italic>atg16l1</italic> (<xref rid="B18" ref-type="bibr">18</xref>), <italic>irmg</italic> (<xref rid="B19" ref-type="bibr">19</xref>), and <italic>nod2</italic> (<xref rid="B20" ref-type="bibr">20</xref>)]; and <italic>epithelial barrier</italic> [<italic>jak2</italic> (<xref rid="B13" ref-type="bibr">13</xref>) and <italic>il-10</italic> (<xref rid="B14" ref-type="bibr">14</xref>)]. These mutations affect the capacity of the innate immune cells to handle intracellular bacteria due to an aberrant autophagy process. These alterations result in a response unable to control systemic bacteria spread, which predisposes the host to an increased pathogen colonization and an enhanced susceptibility to these diseases (<xref rid="B21" ref-type="bibr">21</xref>). Another gene involved in CD is <italic>nod2</italic>, which encodes the nucleotide-binding oligomerization domain-containing protein 2 (NOD2). This gene is in chromosome 16 and encodes an intracellular receptor for the muramyl dipeptide (MDP), a component of bacterial cell wall. When this gene is silenced, it is observed that an aberrant IL-1&#x003b2; production occurs in response to bacterial endotoxins, which leads to an impaired early immune response (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). Mutation in <italic>nod2</italic> also affects the function of Paneth cells, diminishing the production of &#x003b1;-defensin, an antimicrobial peptide secreted by this type of cells (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Variants of this gene, combined with polymorphisms in <italic>tlr9</italic> or <italic>atg16l1</italic>, increase the risk of suffering IBD (<xref rid="B22" ref-type="bibr">22</xref>). The <italic>atg16l1</italic> gene encodes a key protein in the process of autophagy (<xref rid="B9" ref-type="bibr">9</xref>), which is required for a proper innate immune response against microorganisms. Mice ATG16L1<sup>HM</sup>, which carry a disruption of the <italic>atg16l1</italic> gene with a concomitant decreased protein level, display abnormal Paneth cells function due to a defect of the granule exocytosis pathway. Such a phenotype can also be observed in CD patients. In consequence, the secretion of lysozyme is altered, and the expression of genes involved in injury response is increased (<xref rid="B26" ref-type="bibr">26</xref>). These data indicate that Paneth cells have a unique sensitivity to autophagy gene disruption, which lead to endoplasmic reticulum stress in the intestinal epithelium. Thus, the autophagy process could have a specific role in these cells, as it seen in CD patients (<xref rid="B26" ref-type="bibr">26</xref>&#x02013;<xref rid="B28" ref-type="bibr">28</xref>). In another study, researchers found that patients with variants in <italic>nod2</italic> and/or <italic>atg16l1</italic> genes display an increased secretion of TNF-&#x003b1; in response to bacterial translocation through the intestinal epithelial barrier, which is directly related to the aggravation of intestinal inflammation, disease activity, and relapsing episodes (<xref rid="B22" ref-type="bibr">22</xref>). Through genetic analyses, it was shown that CD has more genetic components (such as loci associated with susceptibility to the disease) than does UC (<xref rid="B21" ref-type="bibr">21</xref>). Therefore, a better knowledge of the genetic variables and their interaction with environmental factors will generate a breakthrough in pharmacogenomics, which could be used as a treatment for the disease, improving the tolerability and effectiveness of the therapies used nowadays (<xref rid="B21" ref-type="bibr">21</xref>).</p></sec><sec id="S2"><title>Contribution of the Intestinal Epithelial Barrier to Bacterial Infections and IBD Development</title><p>The intestinal epithelial barrier physically separates the intestinal lumen from deeper layers, such as the lamina propria (<xref rid="B29" ref-type="bibr">29</xref>). It is organized in crypts and villi and composed of four types of specialized cells: <italic>absorptive enterocytes</italic> that have metabolic and digestive functions and can also secrete some antimicrobial peptides; <italic>goblet cells</italic>, specialized in mucus secretion; <italic>enteroendocrine cells</italic> that secrete hormones; and <italic>Paneth cells</italic> that mostly secrete antimicrobial peptides into the crypts of the small intestine (Figure <xref ref-type="fig" rid="F1">1</xref>A) (<xref rid="B29" ref-type="bibr">29</xref>). <italic>M cells</italic>, which are specialized follicle-associated epithelial cells that cover Peyer&#x02019;s patches, are found in the small intestine. The function of these cells is sensing luminal content, a task required for the correct functioning of the epithelial barrier. Antigens and microbes captured by M cells are transported across the epithelial barrier and presented to immune cells residing in the lamina propria, through a process denominated transcytosis, which is essential for antigen-specific mucosal immune response (Figure <xref ref-type="fig" rid="F1">1</xref>A) (<xref rid="B30" ref-type="bibr">30</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Normal intestinal epithelium versus altered intestinal epithelium observed in inflammatory bowel disease (IBD)</bold>. <bold>(A)</bold> The normal intestine presents a high secretion of bactericidal molecules (defensins, REGIII&#x003b3;, and IgA) as mechanisms of defense against pathogenic bacteria. The commensal microbiota inhibits the access of pathogens to the epithelial barrier by competing for nutrients, maintaining homeostasis of the epithelial barrier, and supporting the host immune response. The commensal microbiota is composed of mainly <italic>Firmicutes</italic> and <italic>Bacteroidetes</italic>, and a lower percentage of <italic>Proteobacteria</italic> and <italic>Actinobacteria</italic>. They promote the secretion of mucus and antimicrobial peptides [short-chain fatty acid (SCFA), H2S] and the activation of some pathway of immune system such as the activation of macrophages and dendritic cells in lamina propria, and the production of cytokines such as IL-6, IL-23, and IL-12, which activates Th1 or Th17 cells to produce cytokines acting on intestinal epithelium. <bold>(B)</bold> The intestine of IBD patient has a deregulated response to commensal microbiota by a decrease in the secretion of antimicrobial peptides such as &#x003b1;-defensins and increase in REGIII&#x003b3; as compensatory effect; these effects have relation with defect in Paneth and goblet cells. IBD patients showed lower <italic>Firmicutes</italic> and <italic>Bacteroidetes</italic> but have increased amounts of <italic>Proteobacterias</italic> resulting in a decrease production of SCFA, mucus, and increased inflammation. The epithelium produces an abnormal amount of IgG against commensal microbiota instead IgA. Macrophages produce higher amounts of cytokines that overstimulate Th1 or Th17 cells, which secrete pro-inflammatory cytokines to epithelium.</p></caption><graphic xlink:href="fimmu-08-00191-g001"/></fig><p>Through the intestinal barrier, there are several proteins that monitor the environment of the intestinal lumen. Pattern-recognition receptors (PRRs), for instance, are proteins expressed by different type of innate immune cells located in the intestinal tissue, such as dendritic cells, phagocytic macrophage and granulocytes, cytotoxic natural killer, and &#x003b3;&#x003b4;-T cells; as well as intestinal epithelial cells. PRRs sense pathogens through pathogen-associated molecular patterns (PAMPs), such as LPS or flagellin (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). PRRs also have a role in the regulation of intestinal epithelial barrier, repair, and immune homeostasis (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>). The PRRs include different type of members: toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-I-like receptors (RLRs), and C-type lectin receptors (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>). RLRs and C-type lectin receptors are mainly involved in viral and fungal recognition, respectively (<xref rid="B35" ref-type="bibr">35</xref>). TLRs are present in the surface of epithelial cells and endosomes, and even some can be found inside Paneth cells or enteroendocrine cell (<xref rid="B35" ref-type="bibr">35</xref>). TLRs are distributed in different portions of the intestine and differentially expressed on the apical or basolateral side of the cell. Then, the same PRR may respond differentially depending on its localization. For instance, TLR5 only produces an inflammatory response if it binds flagellin in the basolateral surface of the epithelial barrier, which involves the transcription of pro-inflammatory cytokines (<xref rid="B37" ref-type="bibr">37</xref>). Other proteins involved in pathogen recognition at the intestine are NLRs, which are found in the cytosol of macrophages, dendritic cells, and Paneth cells. These intracellular proteins sense PAMPs as well as endogenous molecules released from damaged cells, called damage-associated molecular patterns. NLRs can sense a distinctive substructure from peptidoglycan of mostly all Gram-negative and Gram-positive bacteria (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B38" ref-type="bibr">38</xref>). Among the NLRs, NOD1 and NOD2 are the most studied. Both recognize products released by division of intracellular bacteria and, after NOD2 is activated, NF-&#x003ba;B translocates to the nucleus and allows the production of IL-6, IL-1&#x003b2;, and TNF-&#x003b1;, to trigger a pro-inflammatory response (<xref rid="B39" ref-type="bibr">39</xref>).</p><p>M cells have another type of receptor, the glycoprotein-2 receptor (GP2), which is found in the apical side of epithelial barrier and serves as transcytosis receptor for many antigens derived from commensal and pathogenic bacteria. This endocytic receptor recognizes FimH, a component of type I pilus of diverse enterobacteria, such as <italic>Escherichia coli</italic> and <italic>Salmonella</italic> Typhimurium. GP2 interacts with bacterial pilus proteins, allowing the capture of the bacterium by the cell and its transport across the barrier to the Peyer&#x02019;s patches and other gut-associated lymphoid tissues (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>).</p><p>Another important component of the intestinal barrier is a wide assortment of resident microbial communities that prevent infection by competing with pathogenic bacteria. For example, commensal bacteria produce secondary metabolites that specifically inhibit members of the same or similar species able to cause infection. It has been shown that there are two bacterial phyla that predominantly reside in the gut of healthy individuals; these are <italic>Bacteroidetes</italic> (Gram-negative) and <italic>Firmicutes</italic> (Gram-positive) (<xref rid="B40" ref-type="bibr">40</xref>). It has been reported that microbial communities may change due to age, nutrition, inflammatory processes, and gastrointestinal disease (Figure <xref ref-type="fig" rid="F1">1</xref>A) (<xref rid="B41" ref-type="bibr">41</xref>), and it has been demonstrated that the presence of commensal microbiota induces a basal expression of certain TLRs (such as TLR2 and TLR5), as compared to the basal levels of expression observed in specific-pathogen free mice and germ free mice (<xref rid="B42" ref-type="bibr">42</xref>). The same report shows that microbiota is essential to trigger a proper inflammatory response to infection by some pathogenic bacteria (<xref rid="B42" ref-type="bibr">42</xref>). Thus, a complex interplay between the host immune system and the microbiota is required for gut microbiota homeostasis. For instance, the production of IL-6 and TNF-&#x003b1; is triggered by commensal microbiota, and a proper functioning of TLR is required for protection against injuries of the intestinal epithelium. Thus, it is possible that the use of antibiotics in pharmacological dose could impair the production of these cytokines due to a reduction of commensal microbiota, which in turn might result in a reduced tissue repair ability (<xref rid="B33" ref-type="bibr">33</xref>).</p><p>A defect in the functioning of any of the epithelial barrier components mentioned above leads to an aberrant inflammatory response and promotes susceptibility to some diseases, such as IBD. In this case, it is known that defects in the response of goblet and/or Paneth cells generate a type of colitis or a spontaneous inflammation that resembles CD (<xref rid="B29" ref-type="bibr">29</xref>). Further, the dual role of TLRs could be also an important factor in the development of the disease (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>).</p></sec><sec id="S3"><title>Defects in the Immune Response to Bacterial Pathogens and Microbiota Described in IBD Patients</title><p>As discussed above, the gut is constantly exposed to commensal microbiota and foreign microorganisms introduced by food consumption. The immune system helps to keep the correct homeostasis between the immunosuppressive response&#x02014;which prevents overreaction to harmless antigens&#x02014;and the protective response against pathogens (<xref rid="B44" ref-type="bibr">44</xref>). Intestinal tissue is highly deteriorated in IBD patients, especially in CD patients, due to an uncontrolled reaction of the immune system against bacterial antigens (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>). Thus, the epithelium is highly affected, and a pro-inflammatory response results in a loss of tolerance to the normal microbiota (Figure <xref ref-type="fig" rid="F1">1</xref>B) (<xref rid="B45" ref-type="bibr">45</xref>).</p><p>Several alterations in mechanisms of epithelial barrier protection are related to the pathology of patients with IBD, because a barrier dysfunction leads to impaired immune responsiveness, as in this disease. One of them is, for example, the secretion of mucus by goblet cells. IBD patients have decreased production and secretion of mucin-2, the main component of the mucus, which is related to the development of inflammation (<xref rid="B46" ref-type="bibr">46</xref>). This leads to a decreased protection of the epithelial barrier and a greater number of bacteria that are in direct contact with the epithelium (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>). Accordingly, mice lacking the gene encoding Muc2 (Muc2<sup>&#x02212;/&#x02212;</sup>) have increased gut inflammation and weight loss, and this deficiency could contribute to the onset and perpetuation of the colitis. Beside this, it is important to mention that the microbiota has an important role in regulating the secretion of colonic mucus (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B48" ref-type="bibr">48</xref>).</p><p>The process of epithelial regeneration after an injury is also affected in IBD patients. Epithelial repair processes are divided in two phases: the first one involves the re-distribution of the existing cells, a process that is regulated by TGF-&#x003b2;. In the second phase, cell proliferation is regulated by cytokines such as IL-6, secreted by pro-inflammatory lymphocytes (<xref rid="B27" ref-type="bibr">27</xref>). TGF-&#x003b2; levels are increased in active UC and CD patients, relative to control patients, due to a constant inflammatory process and injury of the epithelial barrier that must be repaired (<xref rid="B49" ref-type="bibr">49</xref>). IL-6 is induced early after injury, allowing proliferation of intestinal epithelial cells that is needed for a proper healing of the epithelium but also has functionality in tumorigenesis and chronic inflammation. These functions may be related to the development of cancer in IBD patient, having a central role in the pathophysiology of the disease (<xref rid="B50" ref-type="bibr">50</xref>&#x02013;<xref rid="B52" ref-type="bibr">52</xref>). Although the blockage of these pathways did not improve the histopathological score, it does improve disease activity score, and it may have a therapeutic potential (<xref rid="B53" ref-type="bibr">53</xref>).</p><p>As previously discussed, the epithelial barrier must be functional and not allow the entry of pathogens to the inner layers. If the tight junctions are altered, the permeability of the barrier could increase and, along with this, there will be a greater paracellular flow of microorganisms, promoting the infection of the lamina propria with pathogenic and/or opportunistic bacteria (<xref rid="B54" ref-type="bibr">54</xref>). It has been described that both TNF-&#x003b1; and IFN-&#x003b3; can modify these junction structures, and it is known that IBD patients have an elevated production of TNF-&#x003b1;, which could be mediating the increased permeability due to the loss of tight junctions structure (<xref rid="B54" ref-type="bibr">54</xref>). However, it is not well understood if this dysfunction is a consequence of increased inflammation during an active disease or if it is the cause of IBD development, because some susceptible patients without symptoms or those in remission also show altered intestinal permeability (<xref rid="B55" ref-type="bibr">55</xref>). In normal conditions, the intestine is the major antibody producer tissue of the body, and the intestinal mucous membrane contains more than 80% of the activated B cells (<xref rid="B56" ref-type="bibr">56</xref>). IBD patients have a dysfunction in the B cell response, which involves an abnormal mucosal secretion of IgG antibodies against commensal bacteria instead of the physiological secretion of IgA (Figure <xref ref-type="fig" rid="F1">1</xref>B) (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>). This overproduction causes an exacerbated pro-inflammatory response and injury in the epithelium, which is not observed in healthy individuals and may be relevant in the development of the disease (<xref rid="B59" ref-type="bibr">59</xref>). Further, IBD patients also present antibodies to self-antigens or cross-reactivity against several bacterial and fungal antigens, which often precedes the onset of the disease (<xref rid="B60" ref-type="bibr">60</xref>). For example, CD patients have antibodies against <italic>Saccharomyces cerevisiae</italic> (ASCA), <italic>E. coli, Pseudomonas fluorescens</italic>, and flagellin (<xref rid="B61" ref-type="bibr">61</xref>), which are directly related to the aggravation of the disease. Overreaction to these bacterial antigens generates additional clinical manifestations, such as stenosis and internal perforations.</p></sec><sec id="S4"><title>Effect of Antibiotic Treatment in IBD Patients</title><p>Inflammatory bowel disease is characterized by an augmented bacterial density at the mucosal level (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>), as well a diminished number of anti-inflammatory commensal bacteria, such as the Gram-positives <italic>Firmicutes</italic> and <italic>Actinobacteria</italic> (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B64" ref-type="bibr">64</xref>). As a consequence of this dysbiosis (dysregulation of commensal microbiota), an increased number of potentially harmful bacteria (such as Enterobacteriaceae) can occur, producing inflammation (<xref rid="B65" ref-type="bibr">65</xref>). For these reasons, maintaining a proper ratio of these populations is highly relevant, because they constitute a barrier against pathogenic bacteria (<xref rid="B56" ref-type="bibr">56</xref>). In support of this idea, studies have shown that UC patients, even in remission, have dysbiosis when compared to controls, with increased numbers of opportunistic pathogens such as <italic>Campylobacter</italic> spp. and <italic>Helicobacter</italic> spp. (<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>). Further, these patients show a reduction in the number of the cluster related to the metabolism of short-chain fatty acids (SCFAs), which generates less anti-inflammatory environment in their guts (<xref rid="B66" ref-type="bibr">66</xref>). For these reasons, the use of antibiotic in IBD patients to treat septic complication, such as abscesses and wound infection, is still conflicting because it decreases the number of intestinal bacteria and alters the normal composition of the microbiota (<xref rid="B68" ref-type="bibr">68</xref>). Moreover, treatment with antibiotics increases the susceptibility of the patient to acquire an infection by <italic>Clostridium difficile</italic> (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>).</p><p>Along the same line, some studies have shown that antibiotic therapy is functional in UC and in CD, and the therapy works better if given orally. Two meta-analysis supports the role of the antibiotics in induction of the remission of IBD (<xref rid="B70" ref-type="bibr">70</xref>), specifically UC (<xref rid="B71" ref-type="bibr">71</xref>). This observation agrees with a study performed in some pediatric patients with severe refractory UC, where the children receive a triple therapy for 2&#x02013;3&#x02009;weeks with amoxicillin, metronidazole, and doxycycline in children over 7&#x02009;years of age. This study shows that the treatment induced remission in 47% of the patients and the effects observed depend on the physiological characteristics of the patients and the current treatment used to ameliorate the symptoms (<xref rid="B69" ref-type="bibr">69</xref>). A systematic review shows that the induction of remission can occur in both CD and UC patients, but that is still not sufficient information to recommend a type or a cocktail of antibiotic to treat effectively the disease (<xref rid="B72" ref-type="bibr">72</xref>). In summary, most of the processes described above, which can promote the onset and severity of IBD, are related to proper bacterial location and clearance in the intestine. In the next section, we will discuss how pathogenic bacterial infection could trigger IBD in susceptible individuals.</p></sec><sec id="S5"><title><italic>Salmonella enterica</italic> Infection and IBD</title><p>Many pathogenic microorganisms have been implicated in the exacerbation or development of IBD (<xref rid="B73" ref-type="bibr">73</xref>): <italic>Campylobacter</italic> (<xref rid="B1" ref-type="bibr">1</xref>), <italic>E. coli</italic> (<xref rid="B74" ref-type="bibr">74</xref>), <italic>Helicobacter pylori</italic> (<xref rid="B75" ref-type="bibr">75</xref>), <italic>Mycobacterium avium</italic> subspecies <italic>paratuberculosis</italic> (<xref rid="B76" ref-type="bibr">76</xref>), and <italic>C. difficile</italic> (<xref rid="B77" ref-type="bibr">77</xref>). We will focus on <italic>S. enterica</italic> serovar Typhimurium (<xref rid="B1" ref-type="bibr">1</xref>).</p><p><italic>Salmonella enterica</italic> serovar Typhimurium (<italic>S</italic>. Typhimurium) is a facultative, Gram-negative and intracellular bacterium, which infects several host including humans (<xref rid="B78" ref-type="bibr">78</xref>). <italic>S</italic>. Typhimurium can cause a severe inflammation of the intestinal mucosal epithelium, resulting in humans, gastroenteritis, and in mice, typhoid-like systemic illness (<xref rid="B78" ref-type="bibr">78</xref>). As every pathogen, <italic>S</italic>. Typhimurium has several virulence genes, located in at least five <italic>Salmonella</italic> pathogenicity islands (SPIs), which are genetic elements within the <italic>Salmonella</italic> chromosome that was acquired probably by horizontal gene transfer (<xref rid="B79" ref-type="bibr">79</xref>). The most important and more studied SPIs are SPI-1 and SPI-2. Both SPIs encode type III secretion systems (T3SS). These are complex machineries formed by more than 20 proteins that allow contact-dependent translocation of a set of different effector proteins into the eukaryotic cytoplasm (<xref rid="B80" ref-type="bibr">80</xref>, <xref rid="B81" ref-type="bibr">81</xref>). SPI-1 allows <italic>Salmonella</italic> to invade epithelial cells, while SPI-2 allows the survival and replication inside phagocytic cells (<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B82" ref-type="bibr">82</xref>).</p><p>The first step in <italic>S</italic>. Typhimurium infection is to cross the intestinal epithelial barrier, which can be accomplished through four different routes (<xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B84" ref-type="bibr">84</xref>). The main route is through the activation of virulence factors encoded in SPI-1. A second route of invasion requires the rupture of tight junctions of the epithelial cells, which changes the basal permeability of the intestinal barrier (<xref rid="B85" ref-type="bibr">85</xref>). Finally, there is another entry through CX3CR1<sup>+</sup> DCs (<xref rid="B86" ref-type="bibr">86</xref>) interleaved in the epithelial barrier, reaching the bloodstream to spread to extraintestinal sites, through the transport in CD18<sup>+</sup> phagocytes (<xref rid="B87" ref-type="bibr">87</xref>).</p><p>The second step in the cycle of infection of <italic>S</italic>. Typhimurium is the expression of T3SS-2 inside immune cells, such as macrophages and DCs of the Peyer&#x02019;s patches and lamina propria (<xref rid="B88" ref-type="bibr">88</xref>), in which this bacterium can survive and replicate within a specific compartment known as <italic>Salmonella</italic>-containing vacuole (SCV), which avoids lysosomal degradation and antigen presentation (<xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B84" ref-type="bibr">84</xref>). This initial invasion of the Peyer&#x02019;s patches leads to an inflammatory response with recruitment of immune cells, mainly neutrophils, which should prevent bacterial dissemination (Figure <xref ref-type="fig" rid="F2">2</xref>D).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Effect of <italic>Salmonella</italic> infection in inflammatory bowel disease (IBD) patients</bold>. In genetically susceptible to IBD patients, many parameters are disrupted. <bold>(A)</bold> Paneth cells have an impaired secretion of antimicrobial peptides showing a decrease in the amounts of &#x003b1;-defensins, as well as increased amounts of REGIII&#x003b3;, which is associated with impaired protection against pathogens. <bold>(B)</bold> Plasma cells have a polarized antibodies&#x02019; secretion to the production of IgG antibodies targeting the individual&#x02019;s own microbiota. Beside this, the proportions of commensal microorganisms present are unbalanced related to a healthy host. Due to this imbalance, there is a decrease production of short-chain fatty acid (SCFA), which generates an increase in inflammation. Taken together, these effects generate an environment more vulnerable to further infection. Furthermore, <bold>(C)</bold>
<italic>S</italic>. Typhimurium recruits neutrophils to the lumen, which generates ROS, producing tetrathionate in the intestinal lumen; this compound is used by <italic>Salmonella</italic> as electron acceptor, which gives advantage to <italic>S</italic>. Typhimurium over the microbiota. <bold>(D)</bold>
<italic>Salmonella</italic> infection is produced by the entry through DCs interspersed in the epithelial barrier or M cells that recognize it through glycoprotein-2, accessing to the Peyer&#x02019;s patches. <bold>(E)</bold>
<italic>Salmonella</italic> can also get into the epithelial cells forming membrane ruffling or through disruptions of tight junctions caused by itself and in this case especially in inflamed epithelium of IBD patients. <bold>(F)</bold> In the basolateral side, <italic>Salmonella</italic> can be recognized by TLR5 stimulating an increased production of NF-&#x003ba;&#x003b2;, which correlates with an enhanced recruitment of neutrophils, finally once within the epithelial cells, <italic>Salmonella</italic> blocks the autophagosome pathway avoiding its own degradation.</p></caption><graphic xlink:href="fimmu-08-00191-g002"/></fig></sec><sec id="S6"><title>Immune Response Against <italic>Salmonella</italic></title><p>Commensal microbiota, mucus layers, antimicrobial peptides, and tight junctions work together to maintain the integrity of the epithelial cellular barrier and prevent infection of pathogenic bacteria (<xref rid="B89" ref-type="bibr">89</xref>). Despite all these defense mechanisms, <italic>S</italic>. Typhimurium can modify tight junctions to increase the permeability of the barrier, which allows its translocation through the epithelial cell monolayer, due to the secretion of a protein-denominated AvrA through the T3SS-1 (<xref rid="B85" ref-type="bibr">85</xref>). This protein impaired the activation of pro-inflammatory cytokine, such as IL-6 (<xref rid="B90" ref-type="bibr">90</xref>) and can affect cellular proliferation activating the &#x003b2;-catenin pathway (<xref rid="B91" ref-type="bibr">91</xref>). Beside this, AvrA can modulate the c-Jun N-terminal kinase, which suppresses the apoptosis process during early steps of the infectious process (<xref rid="B92" ref-type="bibr">92</xref>). All these mechanisms together allow <italic>S</italic>. Typhimurium to produce inflammation of the intestine, without destroying the epithelium.</p><p>Toll-like receptors and NLRs recognize various compounds of <italic>S</italic>. Typhimurium, activating pathways associated with a pro-inflammatory response such as pyroptosis, which is a cell death response that involves the production of caspase-1, required for the secretion of mature IL-1&#x003b2; and IL-18 by macrophages (<xref rid="B93" ref-type="bibr">93</xref>, <xref rid="B94" ref-type="bibr">94</xref>). For example, flagellin is recognized by TLR5 in the basolateral surface (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B37" ref-type="bibr">37</xref>), which actively promotes the production of pro-inflammatory cytokines, such as IL-6 (<xref rid="B95" ref-type="bibr">95</xref>) and IL-8 (<xref rid="B96" ref-type="bibr">96</xref>), through the activation of the transcription factor NF-&#x003ba;B and MAP kinases, followed by the recruitment of inflammatory cells and the activation of the adaptive immune response. Although immune cells rapidly clear bacteria, an important fraction disseminates to deeper organs using phagocytic cells as a &#x0201c;Trojan horse.&#x0201d; Using this mechanism, <italic>S</italic>. Typhimurium can migrate from the site of infection to the lymph nodes and activate T cells (<xref rid="B97" ref-type="bibr">97</xref>). In addition, <italic>S</italic>. Typhimurium can induce the production of caspase-1 <italic>via</italic> Nlrc4 (a type of NLR) through the recognition of flagellin, which enters through the T3SS-1 to the cytosol of phagocytic cells. This cytosolic response is independent of the one generated by TLR5 (extracellular) (<xref rid="B36" ref-type="bibr">36</xref>). In this way, <italic>S</italic>. Typhimurium uses this defense mechanism (production of inflammasome and pyroptosis process) to spread to other immune cells and disseminate systemically from the gastrointestinal tract (<xref rid="B93" ref-type="bibr">93</xref>).</p><p>During an infection with <italic>S</italic>. Typhimurium, the response of NOD1 or NOD2 occurs through the activation of the transcription factor NF-&#x003ba;B, which has an important role in the regulation of cytokine production. Thereby, it modulates the transmigration of neutrophils to the source of infection and thus the intensity of the inflammation (Figure <xref ref-type="fig" rid="F2">2</xref>F). The activation of another signaling cascade <italic>via</italic> NOD2, triggered also by MDP, has a direct relation with the activation of the inflammasome NLRP3 through NF-&#x003ba;B, caspase-1, and the consequent secretion of IL-1&#x003b2; and IL-18 (<xref rid="B98" ref-type="bibr">98</xref>, <xref rid="B99" ref-type="bibr">99</xref>). The correct function of these receptors is important, because through its activation they interact directly with the ATG16L1 protein and lead to the proper initiation of the autophagy process (<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B100" ref-type="bibr">100</xref>).</p><p>All these effects produce an increase in inflammation after bacterial infection because of the structure loss of the intestinal mucosa, producing diarrhea with concomitant loss of liquid and electrolytes (<xref rid="B97" ref-type="bibr">97</xref>). This response against foreign microorganisms must be controlled to reduce tissue damage or to prevent a systemic infection, as it could be the case of <italic>S</italic>. Typhimurium (Figure <xref ref-type="fig" rid="F2">2</xref>B). However, sometimes the immune response is altered and generates an overreaction against its own components, as in the case of IBD.</p></sec><sec id="S7"><title><italic>Salmonella</italic> Interaction with Microbiota</title><p>Commensal microbiota is mostly fermentative and produces at least three SCFAs, which are mainly acetate, propionate, and butyrate (<xref rid="B101" ref-type="bibr">101</xref>). The concentration and distribution of these compounds vary along the gut and exert different effects on colonization of pathogenic bacteria, such as <italic>Salmonella</italic>. In the ileum, there are higher concentrations of acetate, which induce the expression of genes within SPI-1, allowing the invasion of the ileum (<xref rid="B101" ref-type="bibr">101</xref>). Moreover, propionate and butyrate are present in higher amounts in colon and cecum (<xref rid="B102" ref-type="bibr">102</xref>) playing an antimicrobial effect, diminishing the expression of the same invasion genes (<xref rid="B101" ref-type="bibr">101</xref>&#x02013;<xref rid="B103" ref-type="bibr">103</xref>). Therefore, SCFAs produced by the microbiota influence <italic>S</italic>. Typhimurium&#x02019;s &#x0201c;choice&#x0201d; of the site of colonization, and given that any change in the composition of the microbiota will vary the proportion of these compounds, they could allow for a different disease phenotype.</p><p><italic>S</italic>. Typhimurium infection produces the transmigration of neutrophils, which oxidize the endogen sulfur compound thiosulfate <inline-formula><mml:math id="M1"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mtext>S</mml:mtext><mml:mn>2</mml:mn></mml:msub><mml:msubsup><mml:mtext>O</mml:mtext><mml:mn>3</mml:mn><mml:mrow><mml:mn>2</mml:mn><mml:mo>&#x02212;</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> in the intestinal lumen, generating tetrathionate <inline-formula><mml:math id="M2"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mtext>S</mml:mtext><mml:mn>4</mml:mn></mml:msub><mml:msubsup><mml:mtext>O</mml:mtext><mml:mn>6</mml:mn><mml:mrow><mml:mn>2</mml:mn><mml:mo>&#x02212;</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> (Figure <xref ref-type="fig" rid="F2">2</xref>C) (<xref rid="B104" ref-type="bibr">104</xref>, <xref rid="B105" ref-type="bibr">105</xref>). This product is an electron acceptor for <italic>S</italic>. Typhimurium energetic processes and allows the utilization of ethanolamine as a nutrient by the bacterium. This is a competitive advantage over the fermentative bacteria from the microbiota, which are unable to use this product, so <italic>S</italic>. Typhimurium will overgrow and disseminate (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B105" ref-type="bibr">105</xref>, <xref rid="B106" ref-type="bibr">106</xref>). Beside this, neutrophils induce the change of microbiota during an infection with <italic>S</italic>. Typhimurium secreting a serine protease (elastase), which has a direct effect to the microbiota (<xref rid="B107" ref-type="bibr">107</xref>). This way, <italic>S</italic>. Typhimurium used both the inflammation and the secretion of elastase to create a more favorable environment for its own colonization. <italic>S</italic>. Typhimurium can take advantage of the inflammatory response and promote its own growth and dissemination into host tissues. Moreover, this pathogen could play an important role in changing the microbiota composition in genetic susceptible individuals or patients with a chronic inflammation, such as IBD, due to mainly the dysbiosis in these patients (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B108" ref-type="bibr">108</xref>).</p></sec><sec id="S8"><title><italic>S</italic>. Typhimurium Infection: Previous or after IBD Onset?</title><p>In this section, we will discuss some factors that could relate the intestinal inflammation that occurs in IBD and the intestinal infection caused by <italic>S</italic>. Typhimurium (Figure <xref ref-type="fig" rid="F2">2</xref>). A previous study suggests a connection between <italic>S</italic>. Typhimurium infection and IBD development (<xref rid="B1" ref-type="bibr">1</xref>). Furthermore, another study describes the presence of <italic>Salmonella</italic> and other enteropathogen toxins in the serum of IBD patients, which correlates to disease progression (<xref rid="B109" ref-type="bibr">109</xref>). However, a following study in Danish population suggested that increased detection of <italic>Salmonella</italic> and <italic>Campylobacter</italic> in stools of IBD patients is due to detection bias during the first year of infection (<xref rid="B110" ref-type="bibr">110</xref>). Although no association of exposure to <italic>S. enterica</italic> in CD patients was observed in a study made in another cohort of patient, a relation between CD, cigarette smoking, and anti-<italic>Salmonella</italic> antibodies in serum was observed (<xref rid="B111" ref-type="bibr">111</xref>). However, some studies suggest that during the course of IBD, due to the dysbiosis of the disease itself, the chances of an infection by enteropathogens are higher (<xref rid="B108" ref-type="bibr">108</xref>, <xref rid="B112" ref-type="bibr">112</xref>). Other studies showing positive results with antibiotics treatment of IBD suggest the possibility of a pathogenic agent as the causative agent of the disease (<xref rid="B72" ref-type="bibr">72</xref>).</p><p>The permeability of the epithelium in IBD patients is altered and allows increased transcytosis of commensal and/or pathogenic bacteria, which could generate an inflammatory response. When an infection with an invasive bacterial pathogen (such as <italic>S</italic>. Typhimurium) occurs, it generates the recognition by basolateral TLR5 (Figures <xref ref-type="fig" rid="F2">2</xref>E,F), which initiates an inflammatory immune response (<xref rid="B37" ref-type="bibr">37</xref>). It has been shown that the signaling through TLR5 after flagellin recognition in a murine model of chemical-induced colitis generates an increase in the secretion of pro-inflammatory cytokines (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B96" ref-type="bibr">96</xref>) such as IL-8, which recruits neutrophils to the site of infection (<xref rid="B113" ref-type="bibr">113</xref>) and aggravates the clinical symptoms, producing severe histopathological damage in the colonic mucosa (<xref rid="B32" ref-type="bibr">32</xref>). Therefore, IBD patients can be more susceptible to an infection with a pathogen as <italic>S</italic>. Typhimurium, which could trigger the onset or aggravate the course of the disease, leading to a relapse. Additionally, <italic>S</italic>. Typhimurium synthesizes FimH, a protein that binds to M cells by interacting with GP2. GP2 has an epitope recognized by &#x0201c;anti-pancreatic&#x0201d; antibodies found in CD patients (<xref rid="B114" ref-type="bibr">114</xref>), which could be a consequence of infection with this pathogen or could involve the need for the combination between the receptor and FimH to produce antibodies.</p><p>A deregulation of the secretory function of Paneth cells has been observed in IBD patients. For instance, CD patients have diminished production of &#x003b1;-defensins at both mRNA and protein levels. Further, IBD patients have also an augmented secretion of Reg-lectin family members, such as RegIII&#x003b3;, which has a compensatory effect in the decrease in &#x003b1;-defensins (Figure <xref ref-type="fig" rid="F2">2</xref>A). This phenomenon is related to the increased adherence of the commensal microbiota to the enteric mucosa and an augmented penetration of the commensal bacteria to the mesenteric lymph nodes, which generates an inflammatory environment (<xref rid="B115" ref-type="bibr">115</xref>). All these impaired processes are being observed in the ileum of affected IBD patients and are more pronounced in individuals that also carry mutations in the <italic>nod2</italic> gene. However, these defects <italic>per se</italic> are not translated in increased inflammation of the intestine, which suggests that an additional trigger (such as bacterial infection) may promote IBD in these susceptible patients (<xref rid="B116" ref-type="bibr">116</xref>, <xref rid="B117" ref-type="bibr">117</xref>). A recent study has described that the polymorphism T300A in the gene <italic>atg16l1</italic> results in a defective production of C-type lectin domain family 12 member A (CLEC12A) in CD patients, a protein potentially involved in antibacterial autophagy (<xref rid="B118" ref-type="bibr">118</xref>). This study shows that absence of CLEC12A prevents <italic>S</italic>. Typhimurium clearance by HeLa cells and that mice lacking CLEC12A are more susceptible to suffer a more severe infection (<xref rid="B118" ref-type="bibr">118</xref>). As mentioned above, mutations in the <italic>atg16l1</italic> gene also alter the function of Paneth cells due to changes in the granule exocytosis pathway (<xref rid="B26" ref-type="bibr">26</xref>). In the same context, <italic>S</italic>. Typhimurium diminishes the granules production and the secretion of lysozymes by Paneth cells, through the activation of p38/MAPK in the small intestine (<xref rid="B117" ref-type="bibr">117</xref>). This could be a survival mechanism of the bacterium and may be required by the subsequent infection process. Beside this, the infection activates a differentiation program that results in hyperplasia of Paneth cells in crypts, which could give as a result an acute inflammatory response and have some effect in the intestinal stem cells, due to an accelerated process of proliferation (<xref rid="B119" ref-type="bibr">119</xref>). Further, <italic>S</italic>. Typhimurium generates hyperplasia of Paneth cells through the activation of the Wnt pathway, but IBD patients have deficiencies in different factors (such as Tcf4, for example) of the same pathway, which is related to decrease the secretion of &#x003b1;-defensin (<xref rid="B120" ref-type="bibr">120</xref>) (Figure <xref ref-type="fig" rid="F2">2</xref>A). The combination of virulence factors displayed by <italic>S</italic>. Typhimurium and the genetic alterations of the host that prevent correct bacterial clearance suggests that an infection with <italic>S</italic>. Typhimurium in a susceptible host could generate changes in the proliferation and differentiation of Paneth cells, which in patients suffering IBD will exacerbate the defect produced by the mutation in some of the genes related to this pathology, which finally will modify the lysozyme secretion, with a consequent alteration in microbiota. All these changes generate a new or different niche to the infection and finally the onset of the disease with possible different phenotypes.</p><p>Other important factor related to IBD and <italic>S</italic>. Typhimurium infection is the formation of autophagosomes. <italic>S</italic>. Typhimurium survives inside the SCV without being recognized by the host cell. However, if this compartment is damaged, ubiquitination can modify the bacterium, leading to its autophagy encapsulation. Despite this, Ssel, a soluble protein secreted by T3SS, actively deubiquitinates the bacterium to prevent formation of the autophagosome (<xref rid="B121" ref-type="bibr">121</xref>). In this context, the intestinal epithelium responds to a <italic>S</italic>. Typhimurium infection with increased secretion of factors related to the autophagosome formation (<xref rid="B121" ref-type="bibr">121</xref>). Therefore, the activation of this pathway is one of the main processes required for resolution of the infection caused by this intracellular bacterium. In IBD patients, there are three genes related to the autophagosome process that are affected: <italic>irgm, nod2</italic>, and <italic>atg16l1</italic>, each associated with different grades of susceptibility to suffer IBD, which implies a defect in antigen uptake and its processing, the interaction between dendritic cells and intestinal epithelial cell (<xref rid="B45" ref-type="bibr">45</xref>), and the regulation of PRRs and inflammasome activation. These genes encode proteins that are important to contain the infection caused by <italic>S</italic>. Typhimurium (<xref rid="B122" ref-type="bibr">122</xref>).</p><p>Mutations in the <italic>atg16l1</italic> gene generate defects in the formation of autophagosomes, which implies that lower numbers of bacteria will be captured and so less efficient bacterial clearance will occur (<xref rid="B121" ref-type="bibr">121</xref>, <xref rid="B123" ref-type="bibr">123</xref>). Beside this, patients with CD that carries an <italic>atg16l1</italic> mutation (<xref rid="B45" ref-type="bibr">45</xref>) have an impaired degradation of <italic>S</italic>. Typhimurium, making the host more susceptible to the infection. NOD2 is required for the formation and activation of the phagosome and for the recruitment of ATG16L1 to the site of entry of the bacterium, therefore mutations in this gene generate lower levels of autophagy and an impaired bacterial clearance (<xref rid="B100" ref-type="bibr">100</xref>). Mutation in the <italic>atg16l1</italic> gene impaired the correct antibacterial function of NOD2 in epithelial cells of the colon, and mutation in <italic>nod2</italic> generates an impaired signaling and bacterial killing, but this mutation only partially affects the autophagy process (<xref rid="B124" ref-type="bibr">124</xref>). So, in this case, an infection by <italic>S</italic>. Typhimurium in a susceptible host could be more severe, as proper function of the above mentioned proteins is required for the correct bacterial clearance and for the control of dissemination of <italic>S</italic>. Typhimurium to extraintestinal sites, and this is not necessarily related to the anticipated development of the disease, but it is possible that all these factors could allow the bacteria to survive longer inside the cells and generate an inflammatory atmosphere that promotes the onset of IBD.</p><p>Some studies have demonstrated that MDP induces autophagy in dendritic cells, a process that needs correct NOD2 signaling, which in turn requires mainly the proper function of ATG16L1. These proteins are required for the correct function of NOD2 and antigen presentation (<xref rid="B125" ref-type="bibr">125</xref>). Mutation in this gene generates a malfunction in the autophagy process in dendritic cells, which indicates an aberrant bacterial trafficking and failure to produce antigen presentation on MHC-II molecules, which in turns promote the generation of antigen-specific, effector CD4<sup>+</sup> T cells (<xref rid="B125" ref-type="bibr">125</xref>). All these defects may allow bacteria to survive longer inside dendritic cells, avoiding lysosomal degradation for extended time (<xref rid="B126" ref-type="bibr">126</xref>, <xref rid="B127" ref-type="bibr">127</xref>) and to provide a mechanism for the persistence of the pathogen and in consequence the persistent inflammation. Beside this, it has been reported that <italic>S</italic>. Typhimurium employs dendritic cells expressing CCR7 as a pathway to migrate from the intestine to MLNs (<xref rid="B127" ref-type="bibr">127</xref>).</p><p>The above background suggests that during an infection with <italic>S</italic>. Typhimurium, the bacterial virulence factors and the defective processes in susceptible individuals, such as those described in IBD patients, could generate a persistence of the bacteria in dendritic cells, which would generate a continuous secretion of pro-inflammatory cytokines and an environment of inflammation, which means that an infection with <italic>S</italic>. Typhimurium in these patients could have a double effect, being more permissive to the infection caused by this intracellular bacteria. Because of this, we propose that an infection with <italic>S</italic>. Typhimurium could anticipate the onset of the disease, due to the atmosphere of inflammation that it generates. Furthermore, the infection with <italic>S</italic>. Typhimurium changes the composition of the microbiota and the permeability of the epithelial barrier, which could be a trigger for the disease in susceptible individuals, given that these changes modify the production of cytokines and SCFAs, produce an influx of neutrophils and persistence infection of dendritic cells and, in consequence, generate an abnormal inflammatory environment. All this, combined with a genetic susceptibility, will impair the recognition of pathogens, the autophagy, tissue repair, and bacterial clearance, generating an inflammatory condition at the intestinal epithelium.</p></sec><sec id="S9"><title>Concluding Remarks</title><p>In this review, we discussed several microbial, cellular, and genetic alterations described so far in IBD patients, and related these defects with the infection caused by <italic>S</italic>. Typhimurium. It is possible that <italic>S</italic>. Typhimurium infection could trigger chronic inflammation in individual carrying one or more of the defects associated with IBD, given the inability of these patients to properly clear bacteria in the intestine. Moreover, <italic>S</italic>. Typhimurium has an important arsenal of virulence factors to invade host cells in the intestinal epithelium and lamina propria that the normal microbiota is not able to reach. Additionally, it is known that this bacterium can cause persistent infection in human and in mice, suggesting that in patients displaying one or more genetic defects that predispose to IBD development; it is possible that they are much more susceptible to be infected by <italic>S</italic>. Typhimurium and cause a persistent infection. Permanent infection of cell with <italic>S</italic>. Typhimurium could promote secretion of pro-inflammatory cytokines by infected cells, generating an inflammatory environment in the intestinal layers, promoting changes in the microbiota and promoting chronic diseases. It would be relevant to evaluate whether IBD patients are chronic carriers of <italic>S</italic>. Typhimurium in the intestine.</p><p>Supporting the hypothesis raised in this review, it has been described that IBD patients have a deregulated immune response in the intestine, which is reflected for instance by the secretion of IgG instead of IgA, resulting in an inflammatory response against their own microbiota (<xref rid="B56" ref-type="bibr">56</xref>). This loss of tolerance to the microbiota could be determining factor to the infection with an invasive bacterium as <italic>S</italic>. Typhimurium, which could promote a permanent inflammatory response in the intestine, which in turn could bias the humoral immune response to an IgG type to other bacteria, as the intestinal microflora. It has been described that in IBD patients the commensal microbiota has different phyla proportions in comparison to a healthy person, having less amount of <italic>Bacteroidetes</italic> and <italic>Firmicutes</italic> (beneficial bacteria) (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>). This allows less competition to pathogenic bacteria, making them more invasive. On the other hand, in these patients, the epithelial barrier is impaired because of inflamed epithelial cells, continuous secretion of pro-inflammatory cytokines, and disrupted tight junctions (<xref rid="B54" ref-type="bibr">54</xref>). It is possible that all these alterations could be due to <italic>S</italic>. Typhimurium infection, which results in an increased inflammation in susceptible patients (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B54" ref-type="bibr">54</xref>).</p><p>It is known that <italic>S</italic>. Typhimurium can produce an inflammatory environment due to virulence proteins coded by SPIs, which improve its fitness over intestinal microbiota and, thereby, to reach and invade the epithelium (<xref rid="B79" ref-type="bibr">79</xref>). Therefore, the inflammation would not be detrimental for this kind of invasive pathogen and conversely it might be facilitating growth (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B89" ref-type="bibr">89</xref>, <xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B129" ref-type="bibr">129</xref>). Even more, it is possible that through this mechanism, <italic>S</italic>. Typhimurium can accelerate the development of the disease in people with genetic susceptibility. Due to the factors mentioned above, it is possible that in IBD patients will be more susceptible to suffer a more aggressive infection by <italic>S</italic>. Typhimurium or even to develop a persistent infection, due to the baseline inflammation and impaired intestinal environment. Therefore, the development of new methods that could prevent early colonization with this pathogen in this type of patients is a challenge for future research.</p></sec><sec id="S10"><title>Author Contributions</title><p>All authors listed have made substantial, direct, and intellectual contribution to the work and approved it for publication. The authors are grateful to Pamela A. Nieto, Ph.D., who edited this manuscript.</p></sec><sec id="S11"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><sec id="S12"><title>Funding</title><p>This study was supported by grant numbers 1140010, 1150862, 1161525, and 1131012 from the National Fund for Scientific and Technological Development (FONDECYT) program of the Ministry of Education of Chile and grant Millennium Institute in Immunology and Immunotherapy P09/016-F, from the Iniciativa Cient&#x000ed;fica Milenio of the Ministry of Economy of Chile.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gradel</surname><given-names>KO</given-names></name><name><surname>Nielsen</surname><given-names>HL</given-names></name><name><surname>Sch&#x000f8;nheyder</surname><given-names>HC</given-names></name><name><surname>Ejlertsen</surname><given-names>T</given-names></name><name><surname>Kristensen</surname><given-names>B</given-names></name><name><surname>Nielsen</surname><given-names>H</given-names></name></person-group>. <article-title>Increased short- and long-term risk of inflammatory bowel disease after <italic>Salmonella</italic> or <italic>Campylobacter</italic> gastroenteritis</article-title>. <source>Gastroenterology</source> (<year>2009</year>) <volume>137</volume>:<fpage>495</fpage>&#x02013;<lpage>501</lpage>.<pub-id pub-id-type="doi">10.1053/j.gastro.2009.04.001</pub-id><?supplied-pmid 19361507?><pub-id pub-id-type="pmid">19361507</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlig</surname><given-names>HH</given-names></name><name><surname>Schwerd</surname><given-names>T</given-names></name><name><surname>Koletzko</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>N</given-names></name><name><surname>Kammermeier</surname><given-names>J</given-names></name><name><surname>Elkadri</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>The diagnostic approach to monogenic very early onset inflammatory bowel disease</article-title>. <source>Gastroenterology</source> (<year>2014</year>) <volume>147</volume>:<fpage>990</fpage>&#x02013;<lpage>1007</lpage>.<pub-id pub-id-type="doi">10.1053/j.gastro.2014.07.023</pub-id><?supplied-pmid 25058236?><pub-id pub-id-type="pmid">25058236</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vavricka</surname><given-names>SR</given-names></name><name><surname>Schoepfer</surname><given-names>A</given-names></name><name><surname>Scharl</surname><given-names>M</given-names></name><name><surname>Lakatos</surname><given-names>PL</given-names></name><name><surname>Navarini</surname><given-names>A</given-names></name><name><surname>Rogler</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Extraintestinal manifestations of inflammatory bowel disease in children</article-title>. <source>Inflamm Bowel Dis</source> (<year>2015</year>) <volume>21</volume>:<fpage>1982</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1097/MIB.0000000000000392</pub-id><pub-id pub-id-type="pmid">26154136</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones-Hall</surname><given-names>YL</given-names></name><name><surname>Grisham</surname><given-names>MB</given-names></name></person-group>. <article-title>Immunopathological characterization of selected mouse models of inflammatory bowel disease: comparison to human disease</article-title>. <source>Pathophysiology</source> (<year>2014</year>) <volume>21</volume>:<fpage>267</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="doi">10.1016/j.pathophys.2014.05.002</pub-id><?supplied-pmid 24935242?><pub-id pub-id-type="pmid">24935242</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrickson</surname><given-names>BA</given-names></name><name><surname>Gokhale</surname><given-names>R</given-names></name><name><surname>Cho</surname><given-names>JH</given-names></name></person-group>
<article-title>Clinical aspects and pathophysiology of inflammatory bowel disease</article-title>. <source>Society</source> (<year>2002</year>) <volume>15</volume>:<fpage>79</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1128/CMR.15.1.79</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braus</surname><given-names>NA</given-names></name><name><surname>Elliott</surname><given-names>DE</given-names></name></person-group>. <article-title>Advances in the pathogenesis and treatment of IBD</article-title>. <source>Clin Immunol</source> (<year>2009</year>) <volume>132</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2009.02.006</pub-id><?supplied-pmid 19321388?><pub-id pub-id-type="pmid">19321388</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cosnes</surname><given-names>J</given-names></name><name><surname>Gower-Rousseau</surname><given-names>C</given-names></name><name><surname>Seksik</surname><given-names>P</given-names></name><name><surname>Cortot</surname><given-names>A</given-names></name></person-group>. <article-title>Epidemiology and natural history of inflammatory bowel diseases</article-title>. <source>Gastroenterology</source> (<year>2011</year>) <volume>140</volume>:<fpage>1785</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1053/j.gastro.2011.01.055</pub-id><?supplied-pmid 21530745?><pub-id pub-id-type="pmid">21530745</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlinger</surname><given-names>K</given-names></name><name><surname>Gy&#x000f6;rke</surname><given-names>T</given-names></name><name><surname>Mak&#x000f6;</surname><given-names>E</given-names></name><name><surname>Mester</surname><given-names>A</given-names></name><name><surname>Tarj&#x000e1;n</surname><given-names>Z</given-names></name></person-group>. <article-title>The epidemiology and the pathogenesis of inflammatory bowel disease</article-title>. <source>Eur J Radiol</source> (<year>2000</year>) <volume>35</volume>:<fpage>154</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="doi">10.1016/S0720-048X(00)00238-2</pub-id><?supplied-pmid 11000558?><pub-id pub-id-type="pmid">11000558</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaser</surname><given-names>A</given-names></name><name><surname>Blumberg</surname><given-names>RS</given-names></name></person-group>. <article-title>Autophagy, microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease</article-title>. <source>Gastroenterology</source> (<year>2011</year>) <volume>140</volume>:<fpage>1738</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="doi">10.1053/j.gastro.2011.02.048</pub-id><?supplied-pmid 21530740?><pub-id pub-id-type="pmid">21530740</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neuman</surname><given-names>MG</given-names></name><name><surname>Nanau</surname><given-names>RM</given-names></name></person-group>. <article-title>Inflammatory bowel disease: role of diet, microbiota, life style</article-title>. <source>Transl Res</source> (<year>2012</year>) <volume>160</volume>:<fpage>29</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1016/j.trsl.2011.09.001</pub-id><?supplied-pmid 22687961?><pub-id pub-id-type="pmid">22687961</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massironi</surname><given-names>S</given-names></name><name><surname>Rossi</surname><given-names>RE</given-names></name><name><surname>Cavalcoli</surname><given-names>FA</given-names></name><name><surname>Della Valle</surname><given-names>S</given-names></name><name><surname>Fraquelli</surname><given-names>M</given-names></name><name><surname>Conte</surname><given-names>D</given-names></name></person-group>. <article-title>Nutritional deficiencies in inflammatory bowel disease: therapeutic approaches</article-title>. <source>Clin Nutr</source> (<year>2013</year>) <volume>32</volume>:<fpage>904</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1016/j.clnu.2013.03.020</pub-id><?supplied-pmid 23602613?><pub-id pub-id-type="pmid">23602613</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ananthakrishnan</surname><given-names>AN</given-names></name><name><surname>Khalili</surname><given-names>H</given-names></name><name><surname>Konijeti</surname><given-names>GG</given-names></name><name><surname>Higuchi</surname><given-names>LM</given-names></name><name><surname>de Silva</surname><given-names>P</given-names></name><name><surname>Fuchs</surname><given-names>CS</given-names></name><etal/></person-group>
<article-title>Long-term intake of dietary fat and risk of ulcerative colitis and Crohn&#x02019;s disease</article-title>. <source>Gut</source> (<year>2014</year>) <volume>63</volume>:<fpage>776</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1136/gutjnl-2013-305304</pub-id><pub-id pub-id-type="pmid">23828881</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>CA</given-names></name><name><surname>Boucher</surname><given-names>G</given-names></name><name><surname>Lees</surname><given-names>CW</given-names></name><name><surname>Franke</surname><given-names>A</given-names></name><name><surname>D&#x02019;Amato</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>KD</given-names></name><etal/></person-group>
<article-title>Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47</article-title>. <source>Nat Genet</source> (<year>2011</year>) <volume>43</volume>:<fpage>246</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1038/ng.764</pub-id><?supplied-pmid 21297633?><pub-id pub-id-type="pmid">21297633</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>A</given-names></name><name><surname>McGovern</surname><given-names>DP</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Radford-Smith</surname><given-names>GL</given-names></name><name><surname>Ahmad</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Genome-wide meta-analysis increases to 71 the number of confirmed Crohn&#x02019;s disease susceptibility loci</article-title>. <source>Nat Genet</source> (<year>2010</year>) <volume>42</volume>:<fpage>1118</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1038/ng.717</pub-id><pub-id pub-id-type="pmid">21102463</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishihara</surname><given-names>S</given-names></name><name><surname>Aziz</surname><given-names>MM</given-names></name><name><surname>Yuki</surname><given-names>T</given-names></name><name><surname>Kazumori</surname><given-names>H</given-names></name><name><surname>Kinoshita</surname><given-names>Y</given-names></name></person-group>. <article-title>Inflammatory bowel disease: review from the aspect of genetics</article-title>. <source>J Gastroenterol</source> (<year>2009</year>) <volume>44</volume>:<fpage>1097</fpage>&#x02013;<lpage>108</lpage>.<pub-id pub-id-type="doi">10.1007/s00535-009-0141-8</pub-id><?supplied-pmid 19802731?><pub-id pub-id-type="pmid">19802731</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duerr</surname><given-names>RH</given-names></name><name><surname>Taylor</surname><given-names>KD</given-names></name><name><surname>Brant</surname><given-names>SR</given-names></name><name><surname>Rioux</surname><given-names>JD</given-names></name><name><surname>Silverberg</surname><given-names>MS</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><etal/></person-group>
<article-title>A genome-wide association study identifies IL23R as an inflammatory bowel disease gene</article-title>. <source>Science</source> (<year>2006</year>) <volume>314</volume>:<fpage>1461</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1126/science.1135245</pub-id><?supplied-pmid 17068223?><pub-id pub-id-type="pmid">17068223</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Hansoul</surname><given-names>S</given-names></name><name><surname>Nicolae</surname><given-names>DL</given-names></name><name><surname>Cho</surname><given-names>JH</given-names></name><name><surname>Duerr</surname><given-names>RH</given-names></name><name><surname>Rioux</surname><given-names>JD</given-names></name><etal/></person-group>
<article-title>Genome-wide association defines more than thirty distinct susceptibility loci for Crohn&#x02019;s disease</article-title>. <source>Nat Genet</source> (<year>2009</year>) <volume>40</volume>:<fpage>955</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1038/NG.175.Genome-wide</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hampe</surname><given-names>J</given-names></name><name><surname>Franke</surname><given-names>A</given-names></name><name><surname>Rosenstiel</surname><given-names>P</given-names></name><name><surname>Till</surname><given-names>A</given-names></name><name><surname>Teuber</surname><given-names>M</given-names></name><name><surname>Huse</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1</article-title>. <source>Nat Genet</source> (<year>2007</year>) <volume>39</volume>:<fpage>207</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1038/ng1954</pub-id><?supplied-pmid 17200669?><pub-id pub-id-type="pmid">17200669</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massey</surname><given-names>DCO</given-names></name><name><surname>Parkes</surname><given-names>M</given-names></name></person-group>
<article-title>Genome-wide association scanning highlights two autophagy genes, ATG16L1 and IRGM, as being significantly associated with Crohn&#x02019;s disease</article-title>. <source>Autophagy</source> (<year>2007</year>) <volume>3</volume>:<fpage>649</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="doi">10.4161/auto.5075</pub-id><pub-id pub-id-type="pmid">17921695</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hugot</surname><given-names>JP</given-names></name><name><surname>Chamaillard</surname><given-names>M</given-names></name><name><surname>Zouali</surname><given-names>H</given-names></name><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>C&#x000e9;zard</surname><given-names>JP</given-names></name><name><surname>Belaiche</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn&#x02019;s disease</article-title>. <source>Nature</source> (<year>2001</year>) <volume>411</volume>:<fpage>599</fpage>&#x02013;<lpage>603</lpage>.<pub-id pub-id-type="doi">10.1038/35079107</pub-id><pub-id pub-id-type="pmid">11385576</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventham</surname><given-names>NT</given-names></name><name><surname>Kennedy</surname><given-names>NA</given-names></name><name><surname>Nimmo</surname><given-names>ER</given-names></name><name><surname>Satsangi</surname><given-names>J</given-names></name></person-group>. <article-title>Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics</article-title>. <source>Gastroenterology</source> (<year>2013</year>) <volume>145</volume>:<fpage>293</fpage>&#x02013;<lpage>308</lpage>.<pub-id pub-id-type="doi">10.1053/j.gastro.2013.05.050</pub-id><?supplied-pmid 23751777?><pub-id pub-id-type="pmid">23751777</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guti&#x000e9;rrez</surname><given-names>A</given-names></name><name><surname>Scharl</surname><given-names>M</given-names></name><name><surname>Sempere</surname><given-names>L</given-names></name><name><surname>Holler</surname><given-names>E</given-names></name><name><surname>Zapater</surname><given-names>P</given-names></name><name><surname>Almenta</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn&#x02019;s disease</article-title>. <source>Gut</source> (<year>2014</year>) <volume>63</volume>:<fpage>272</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1136/gutjnl-2012-303557</pub-id><pub-id pub-id-type="pmid">23376290</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkes</surname><given-names>M</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Prescott</surname><given-names>NJ</given-names></name><name><surname>Tremelling</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>CA</given-names></name><name><surname>Fisher</surname><given-names>SA</given-names></name><etal/></person-group>
<article-title>Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn&#x02019;s disease susceptibility</article-title>. <source>Nat Genet</source> (<year>2007</year>) <volume>39</volume>:<fpage>830</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="doi">10.1038/ng2061</pub-id><pub-id pub-id-type="pmid">17554261</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>RH</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>XM</given-names></name><name><surname>Ma</surname><given-names>JY</given-names></name><etal/></person-group>
<article-title>Down-regulation of human enteric antimicrobial peptides by NOD2 during differentiation of the Paneth cell lineage</article-title>. <source>Sci Rep</source> (<year>2015</year>) <volume>5</volume>:<fpage>8383</fpage>.<pub-id pub-id-type="doi">10.1038/srep08383</pub-id><?supplied-pmid 25670499?><pub-id pub-id-type="pmid">25670499</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>R</given-names></name><name><surname>Zeng</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Commensal bacteria direct selective cargo sorting to promote symbiosis</article-title>. <source>Nat Immunol</source> (<year>2015</year>) <volume>16</volume>:<fpage>918</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1038/ni.3233</pub-id><?supplied-pmid 26237551?><pub-id pub-id-type="pmid">26237551</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cadwell</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>JY</given-names></name><name><surname>Brown</surname><given-names>SL</given-names></name><name><surname>Miyoshi</surname><given-names>H</given-names></name><name><surname>Loh</surname><given-names>J</given-names></name><name><surname>Lennerz</surname><given-names>JK</given-names></name><etal/></person-group>
<article-title>A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells</article-title>. <source>Nature</source> (<year>2008</year>) <volume>456</volume>:<fpage>259</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1038/nature07416</pub-id><?supplied-pmid 18849966?><pub-id pub-id-type="pmid">18849966</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>R</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name></person-group>
<article-title>Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease</article-title>. <source>J Gastroenterol</source> (<year>2015</year>) <volume>51</volume>(<issue>1</issue>):<fpage>11</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1007/s00535-015-1098-4</pub-id><pub-id pub-id-type="pmid">26138071</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adolph</surname><given-names>TE</given-names></name><name><surname>Tomczak</surname><given-names>MF</given-names></name><name><surname>Niederreiter</surname><given-names>L</given-names></name><name><surname>Ko</surname><given-names>HJ</given-names></name><name><surname>B&#x000f6;ck</surname><given-names>J</given-names></name><name><surname>Martinez-Naves</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Paneth cells as a site of origin for intestinal inflammation</article-title>. <source>Nature</source> (<year>2013</year>) <volume>503</volume>:<fpage>272</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1038/nature12599</pub-id><pub-id pub-id-type="pmid">24089213</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>LW</given-names></name><name><surname>Artis</surname><given-names>D</given-names></name></person-group>
<article-title>Intestinal epithelial cells: regulators of barrier function and immune homeostasis</article-title>. <source>Nat Rev Immunol</source> (<year>2014</year>) <volume>14</volume>:<fpage>141</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1038/nri3608</pub-id><pub-id pub-id-type="pmid">24566914</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hase</surname><given-names>K</given-names></name><name><surname>Kawano</surname><given-names>K</given-names></name><name><surname>Nochi</surname><given-names>T</given-names></name><name><surname>Pontes</surname><given-names>GS</given-names></name><name><surname>Fukuda</surname><given-names>S</given-names></name><name><surname>Ebisawa</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response</article-title>. <source>Nature</source> (<year>2009</year>) <volume>462</volume>:<fpage>226</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1038/nature08529</pub-id><?supplied-pmid 19907495?><pub-id pub-id-type="pmid">19907495</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pastorelli</surname><given-names>L</given-names></name><name><surname>De Salvo</surname><given-names>C</given-names></name><name><surname>Mercado</surname><given-names>JR</given-names></name><name><surname>Vecchi</surname><given-names>M</given-names></name><name><surname>Pizarro</surname><given-names>TT</given-names></name></person-group>. <article-title>Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics</article-title>. <source>Front Immunol</source> (<year>2013</year>) <volume>4</volume>:<fpage>280</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2013.00280</pub-id><?supplied-pmid 24062746?><pub-id pub-id-type="pmid">24062746</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>SH</given-names></name><name><surname>Im</surname><given-names>E</given-names></name><name><surname>Riegler</surname><given-names>M</given-names></name><name><surname>Kokkotou</surname><given-names>E</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>M</given-names></name><name><surname>Pothoulakis</surname><given-names>C</given-names></name></person-group>. <article-title>Pathophysiological role of toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2005</year>) <volume>102</volume>:<fpage>13610</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0502174102</pub-id><?supplied-pmid 16157881?><pub-id pub-id-type="pmid">16157881</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakoff-Nahoum</surname><given-names>S</given-names></name><name><surname>Paglino</surname><given-names>J</given-names></name><name><surname>Eslami-Varzaneh</surname><given-names>F</given-names></name><name><surname>Edberg</surname><given-names>S</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group>. <article-title>Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis</article-title>. <source>Cell</source> (<year>2004</year>) <volume>118</volume>:<fpage>229</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2004.07.002</pub-id><?supplied-pmid 15260992?><pub-id pub-id-type="pmid">15260992</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>ZD</given-names></name><name><surname>Chen</surname><given-names>MS</given-names></name><name><surname>Zhang</surname><given-names>XQ</given-names></name><name><surname>Shen</surname><given-names>LP</given-names></name><name><surname>Zhang</surname><given-names>JX</given-names></name><etal/></person-group>
<article-title>Activation of toll-like receptors by intestinal microflora reduces radiation-induced DNA damage in mice</article-title>. <source>Mutat Res Toxicol Environ Mutagen</source> (<year>2014</year>) <volume>774</volume>:<fpage>22</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.mrgentox.2014.09.001</pub-id><?supplied-pmid 25440907?><pub-id pub-id-type="pmid">25440907</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>O</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group>
<article-title>Pattern recognition receptors and inflammation</article-title>. <source>Cell</source> (<year>2010</year>) <volume>140</volume>:<fpage>805</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2010.01.022</pub-id><pub-id pub-id-type="pmid">20303872</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>GY</given-names></name><name><surname>Nez</surname><given-names>G</given-names></name></person-group>
<article-title>Inflammasomes in intestinal inflammation and cancer</article-title>. <source>Gastroenterology</source> (<year>2011</year>) <volume>141</volume>:<fpage>1986</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="doi">10.1053/j.gastro.2011.10.002</pub-id><pub-id pub-id-type="pmid">22005480</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gewirtz</surname><given-names>AT</given-names></name><name><surname>Navas</surname><given-names>TA</given-names></name><name><surname>Lyons</surname><given-names>S</given-names></name><name><surname>Godowski</surname><given-names>PJ</given-names></name><name><surname>Madara</surname><given-names>JL</given-names></name></person-group>. <article-title>Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression</article-title>. <source>J Immunol</source> (<year>2001</year>) <volume>167</volume>:<fpage>1882</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.167.4.1882</pub-id><?supplied-pmid 11489966?><pub-id pub-id-type="pmid">11489966</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bourhis</surname><given-names>L</given-names></name><name><surname>Magalhaes</surname><given-names>JG</given-names></name><name><surname>Selvanantham</surname><given-names>T</given-names></name><name><surname>Travassos</surname><given-names>LH</given-names></name><name><surname>Geddes</surname><given-names>K</given-names></name><name><surname>Fritz</surname><given-names>JH</given-names></name><etal/></person-group>
<article-title>Role of Nod1 in mucosal dendritic cells during <italic>Salmonella</italic> pathogenicity island 1-independent <italic>Salmonella enterica</italic> serovar Typhimurium infection</article-title>. <source>Infect Immun</source> (<year>2009</year>) <volume>77</volume>:<fpage>4480</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.00519-09</pub-id><?supplied-pmid 19620349?><pub-id pub-id-type="pmid">19620349</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranson</surname><given-names>N</given-names></name><name><surname>Eri</surname><given-names>R</given-names></name></person-group>
<article-title>The role of inflammasomes in intestinal inflammation</article-title>. <source>Am J Med Biol Res</source> (<year>2013</year>) <volume>1</volume>:<fpage>64</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="doi">10.12691/ajmbr-1-3-3</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>DN</given-names></name><name><surname>St Amand</surname><given-names>AL</given-names></name><name><surname>Feldman</surname><given-names>RA</given-names></name><name><surname>Boedeker</surname><given-names>EC</given-names></name><name><surname>Harpaz</surname><given-names>N</given-names></name><name><surname>Pace</surname><given-names>NR</given-names></name></person-group>. <article-title>Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2007</year>) <volume>104</volume>(<issue>34</issue>):<fpage>13780</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0706625104</pub-id><?supplied-pmid 17699621?><pub-id pub-id-type="pmid">17699621</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>SE</given-names></name><name><surname>B&#x000e4;umler</surname><given-names>AJ</given-names></name></person-group>. <article-title>A breathtaking feat: to compete with the gut microbiota, <italic>Salmonella</italic> drives its host to provide a respiratory electron acceptor</article-title>. <source>Gut Microbes</source> (<year>2011</year>) <volume>2</volume>(<issue>1</issue>):<fpage>58</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.4161/gmic.2.1.14911</pub-id><?supplied-pmid 21637020?><pub-id pub-id-type="pmid">21637020</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundin</surname><given-names>A</given-names></name><name><surname>Bok</surname><given-names>CM</given-names></name><name><surname>Aronsson</surname><given-names>L</given-names></name><name><surname>Bj&#x000f6;rkholm</surname><given-names>B</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><name><surname>Pott</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Gut flora, toll-like receptors and nuclear receptors: a tripartite communication that tunes innate immunity in large intestine</article-title>. <source>Cell Microbiol</source> (<year>2008</year>) <volume>10</volume>:<fpage>1093</fpage>&#x02013;<lpage>103</lpage>.<pub-id pub-id-type="doi">10.1111/j.1462-5822.2007.01108.x</pub-id><?supplied-pmid 18088401?><pub-id pub-id-type="pmid">18088401</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakoff-Nahoum</surname><given-names>S</given-names></name><name><surname>Hao</surname><given-names>L</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group>. <article-title>Role of toll-like receptors in spontaneous commensal-dependent colitis</article-title>. <source>Immunity</source> (<year>2006</year>) <volume>25</volume>:<fpage>319</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2006.06.010</pub-id><?supplied-pmid 16879997?><pub-id pub-id-type="pmid">16879997</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fournier</surname><given-names>BM</given-names></name><name><surname>Parkos</surname><given-names>CA</given-names></name></person-group>. <article-title>The role of neutrophils during intestinal inflammation</article-title>. <source>Mucosal Immunol</source> (<year>2012</year>) <volume>5</volume>:<fpage>354</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1038/mi.2012.24</pub-id><?supplied-pmid 22491176?><pub-id pub-id-type="pmid">22491176</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spalinger</surname><given-names>MR</given-names></name><name><surname>Rogler</surname><given-names>G</given-names></name><name><surname>Scharl</surname><given-names>M</given-names></name></person-group>
<article-title>Crohn&#x02019;s disease: loss of tolerance or a disorder of autophagy?</article-title>
<source>Dig Dis</source> (<year>2014</year>) <volume>32</volume>:<fpage>370</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1159/000358140</pub-id><pub-id pub-id-type="pmid">24969282</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Sluis</surname><given-names>M</given-names></name><name><surname>De Koning</surname><given-names>BA</given-names></name><name><surname>De Bruijn</surname><given-names>AC</given-names></name><name><surname>Velcich</surname><given-names>A</given-names></name><name><surname>Meijerink</surname><given-names>JP</given-names></name><name><surname>Van Goudoever</surname><given-names>JB</given-names></name><etal/></person-group>
<article-title>Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection</article-title>. <source>Gastroenterology</source> (<year>2006</year>) <volume>131</volume>:<fpage>117</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="doi">10.1053/j.gastro.2006.04.020</pub-id><?supplied-pmid 16831596?><pub-id pub-id-type="pmid">16831596</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>UA</given-names></name><name><surname>Magnusson</surname><given-names>MK</given-names></name><name><surname>Rydstr&#x000f6;m</surname><given-names>A</given-names></name><name><surname>Jonstrand</surname><given-names>C</given-names></name><name><surname>Hengst</surname><given-names>J</given-names></name><name><surname>Johansson</surname><given-names>ME</given-names></name><etal/></person-group>
<article-title>Spontaneous colitis in Muc2-deficient mice reflects clinical and cellular features of active ulcerative colitis</article-title>. <source>PLoS One</source> (<year>2014</year>) <volume>9</volume>:<fpage>e100217</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0100217</pub-id><?supplied-pmid 24945909?><pub-id pub-id-type="pmid">24945909</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersson</surname><given-names>J</given-names></name><name><surname>Schreiber</surname><given-names>O</given-names></name><name><surname>Hansson</surname><given-names>GC</given-names></name><name><surname>Gendler</surname><given-names>SJ</given-names></name><name><surname>Velcich</surname><given-names>A</given-names></name><name><surname>Lundberg</surname><given-names>JO</given-names></name><etal/></person-group>
<article-title>Importance and regulation of the colonic mucus barrier in a mouse model of colitis</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source> (<year>2011</year>) <volume>300</volume>:<fpage>G327</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1152/ajpgi.00422.2010</pub-id><?supplied-pmid 21109593?><pub-id pub-id-type="pmid">21109593</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babyatsky</surname><given-names>MW</given-names></name><name><surname>Rossiter</surname><given-names>G</given-names></name><name><surname>Podolsky</surname><given-names>DK</given-names></name></person-group>. <article-title>Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease</article-title>. <source>Gastroenterology</source> (<year>1996</year>) <volume>110</volume>:<fpage>975</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1053/gast.1996.v110.pm8613031</pub-id><?supplied-pmid 8613031?><pub-id pub-id-type="pmid">8613031</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coccia</surname><given-names>M</given-names></name><name><surname>Harrison</surname><given-names>OJ</given-names></name><name><surname>Schiering</surname><given-names>C</given-names></name><name><surname>Asquith</surname><given-names>MJ</given-names></name><name><surname>Becher</surname><given-names>B</given-names></name><name><surname>Powrie</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>IL-1b mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells</article-title>. <source>J Exp Med</source> (<year>2012</year>) <volume>209</volume>:<fpage>1595</fpage>&#x02013;<lpage>609</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20111453</pub-id><pub-id pub-id-type="pmid">22891275</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Yoshizaki</surname><given-names>K</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name></person-group>. <article-title>IL-6 is required for the development of Th1 cell-mediated murine colitis</article-title>. <source>J Immunol</source> (<year>2000</year>) <volume>164</volume>:<fpage>4878</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.164.9.4878</pub-id><?supplied-pmid 10779797?><pub-id pub-id-type="pmid">10779797</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>KA</given-names></name><name><surname>Manieri</surname><given-names>NA</given-names></name><name><surname>Liu</surname><given-names>TC</given-names></name><name><surname>Stappenbeck</surname><given-names>TS</given-names></name></person-group>. <article-title>IL-6 stimulates intestinal epithelial proliferation and repair after injury</article-title>. <source>PLoS One</source> (<year>2014</year>) <volume>9</volume>:<fpage>e114195</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0114195</pub-id><?supplied-pmid 25478789?><pub-id pub-id-type="pmid">25478789</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Takazoe</surname><given-names>M</given-names></name><name><surname>Fukuda</surname><given-names>Y</given-names></name><name><surname>Hibi</surname><given-names>T</given-names></name><name><surname>Kusugami</surname><given-names>K</given-names></name><name><surname>Andoh</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn&#x02019;s disease</article-title>. <source>Gastroenterology</source> (<year>2004</year>) <volume>126</volume>:<fpage>989</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1053/j.gastro.2004.01.012</pub-id><pub-id pub-id-type="pmid">15057738</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>JR</given-names></name></person-group>. <article-title>Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application</article-title>. <source>Am J Pathol</source> (<year>2006</year>) <volume>169</volume>:<fpage>1901</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.2353/ajpath.2006.060681</pub-id><?supplied-pmid 17148655?><pub-id pub-id-type="pmid">17148655</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Secondulfo</surname><given-names>M</given-names></name><name><surname>de Magistris</surname><given-names>L</given-names></name><name><surname>Fiandra</surname><given-names>R</given-names></name><name><surname>Caserta</surname><given-names>L</given-names></name><name><surname>Belletta</surname><given-names>M</given-names></name><name><surname>Tartaglione</surname><given-names>MT</given-names></name><etal/></person-group>
<article-title>Intestinal and their permeability first degree in Crohn&#x02019;s relatives disease patients</article-title>. <source>Dig Liver Dis</source> (<year>2001</year>) <volume>33</volume>(<issue>8</issue>):<fpage>680</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/S1590-8658(01)80045-1</pub-id><pub-id pub-id-type="pmid">11785714</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandtzaeg</surname><given-names>P</given-names></name></person-group>. <article-title>Mucosal immunity: induction, dissemination, and effector functions</article-title>. <source>Scand J Immunol</source> (<year>2009</year>) <volume>70</volume>:<fpage>505</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-3083.2009.02319.x</pub-id><?supplied-pmid 19906191?><pub-id pub-id-type="pmid">19906191</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagalingam</surname><given-names>NA</given-names></name><name><surname>Lynch</surname><given-names>SV</given-names></name></person-group>. <article-title>Role of the microbiota in inflammatory bowel diseases</article-title>. <source>Inflamm Bowel Dis</source> (<year>2012</year>) <volume>18</volume>:<fpage>968</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1002/ibd.21866</pub-id><?supplied-pmid 21936031?><pub-id pub-id-type="pmid">21936031</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frehn</surname><given-names>L</given-names></name><name><surname>Jansen</surname><given-names>A</given-names></name><name><surname>Bennek</surname><given-names>E</given-names></name><name><surname>Mandic</surname><given-names>AD</given-names></name><name><surname>Temizel</surname><given-names>I</given-names></name><name><surname>Tischendorf</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Distinct patterns of IgG and IgA against food and microbial antigens in serum and feces of patients with inflammatory bowel diseases</article-title>. <source>PLoS One</source> (<year>2014</year>) <volume>9</volume>:<fpage>e106750</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0106750</pub-id><?supplied-pmid 25215528?><pub-id pub-id-type="pmid">25215528</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homsak</surname><given-names>E</given-names></name><name><surname>Miceti&#x00107;-Turk</surname><given-names>D</given-names></name><name><surname>Bozic</surname><given-names>B</given-names></name></person-group>. <article-title>Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value</article-title>. <source>Wien Klin Wochenschr</source> (<year>2010</year>) <volume>122</volume>:<fpage>19</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1007/s00508-010-1344-y</pub-id><?supplied-pmid 20517666?><pub-id pub-id-type="pmid">20517666</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Israeli</surname><given-names>E</given-names></name><name><surname>Grotto</surname><given-names>I</given-names></name><name><surname>Gilburd</surname><given-names>B</given-names></name><name><surname>Balicer</surname><given-names>RD</given-names></name><name><surname>Goldin</surname><given-names>E</given-names></name><name><surname>Wiik</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Anti-<italic>Saccharomyces cerevisiae</italic> and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease</article-title>. <source>Gut</source> (<year>2005</year>) <volume>54</volume>:<fpage>1232</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1136/gut.2004.060228</pub-id><?supplied-pmid 16099791?><pub-id pub-id-type="pmid">16099791</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertin</surname><given-names>D</given-names></name><name><surname>Grimaud</surname><given-names>JC</given-names></name><name><surname>Lesavre</surname><given-names>N</given-names></name><name><surname>Benelmouloud</surname><given-names>C</given-names></name><name><surname>Desjeux</surname><given-names>A</given-names></name><name><surname>Garcia</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Targeting tissular immune response improves diagnostic performance of anti-<italic>Saccharomyces cerevisiae</italic> antibodies (ASCA) in Crohn&#x02019;s disease</article-title>. <source>PLoS One</source> (<year>2013</year>) <volume>8</volume>(<issue>11</issue>):<fpage>e80433</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0080433</pub-id><pub-id pub-id-type="pmid">24303014</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damaskos</surname><given-names>D</given-names></name><name><surname>Kolios</surname><given-names>G</given-names></name></person-group>
<article-title>Probiotics and prebiotics in inflammatory bowel disease: microflora &#x0201c;on the scope&#x0201d;</article-title>. <source>Br J Clin Pharmacol</source> (<year>2008</year>) <volume>65</volume>:<fpage>453</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2125.2008.03096.x</pub-id><pub-id pub-id-type="pmid">18279467</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fite</surname><given-names>A</given-names></name><name><surname>Macfarlane</surname><given-names>S</given-names></name><name><surname>Furrie</surname><given-names>E</given-names></name><name><surname>Bahrami</surname><given-names>B</given-names></name><name><surname>Cummings</surname><given-names>JH</given-names></name><name><surname>Steinke</surname><given-names>DT</given-names></name><etal/></person-group>
<article-title>Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration</article-title>. <source>J Clin Microbiol</source> (<year>2013</year>) <volume>51</volume>:<fpage>849</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="doi">10.1128/JCM.02574-12</pub-id><?supplied-pmid 23269735?><pub-id pub-id-type="pmid">23269735</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latella</surname><given-names>G</given-names></name><name><surname>Fiocchi</surname><given-names>C</given-names></name><name><surname>Caprili</surname><given-names>R</given-names></name></person-group>
<article-title>News from the &#x0201c;5th international meeting on inflammatory bowel diseases&#x0201d; CAPRI 2010</article-title>. <source>J Crohns Colitis</source> (<year>2010</year>) <volume>4</volume>:<fpage>690</fpage>&#x02013;<lpage>702</lpage>.<pub-id pub-id-type="doi">10.1016/j.crohns.2010.08.002</pub-id><pub-id pub-id-type="pmid">21122584</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>R</given-names></name><name><surname>Cameron</surname><given-names>FL</given-names></name><name><surname>Hold</surname><given-names>GL</given-names></name><name><surname>El-Omar</surname><given-names>EM</given-names></name><name><surname>Russell</surname><given-names>RK</given-names></name></person-group>
<article-title>Inflammatory bowel disease</article-title>. <source>Paediatr Child Health (Oxford)</source> (<year>2010</year>) <volume>20</volume>:<fpage>473</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.paed.2010.04.005</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajili&#x00107;-Stojanovi&#x00107;</surname><given-names>M</given-names></name><name><surname>Shanahan</surname><given-names>F</given-names></name><name><surname>Guarner</surname><given-names>F</given-names></name><name><surname>de Vos</surname><given-names>WM</given-names></name></person-group>. <article-title>Phylogenetic analysis of dysbiosis in ulcerative colitis during remission</article-title>. <source>Inflamm Bowel Dis</source> (<year>2013</year>) <volume>19</volume>:<fpage>481</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1097/MIB.0b013e31827fec6d</pub-id><?supplied-pmid 23385241?><pub-id pub-id-type="pmid">23385241</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemoto</surname><given-names>H</given-names></name><name><surname>Kataoka</surname><given-names>K</given-names></name><name><surname>Ishikawa</surname><given-names>H</given-names></name><name><surname>Ikata</surname><given-names>K</given-names></name><name><surname>Arimochi</surname><given-names>H</given-names></name><name><surname>Iwasaki</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis</article-title>. <source>Dig Dis Sci</source> (<year>2012</year>) <volume>57</volume>:<fpage>2955</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1007/s10620-012-2236-y</pub-id><?supplied-pmid 22623042?><pub-id pub-id-type="pmid">22623042</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nitzan</surname><given-names>O</given-names></name><name><surname>Elias</surname><given-names>M</given-names></name><name><surname>Peretz</surname><given-names>A</given-names></name><name><surname>Saliba</surname><given-names>W</given-names></name></person-group>. <article-title>Role of antibiotics for treatment of inflammatory bowel disease</article-title>. <source>World J Gastroenterol</source> (<year>2016</year>) <volume>22</volume>:<fpage>1078</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="doi">10.3748/wjg.v22.i3.1078</pub-id><?supplied-pmid 26811648?><pub-id pub-id-type="pmid">26811648</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>D</given-names></name><name><surname>Levine</surname><given-names>A</given-names></name><name><surname>Kolho</surname><given-names>KL</given-names></name><name><surname>Shaoul</surname><given-names>R</given-names></name><name><surname>Ledder</surname><given-names>O</given-names></name></person-group>. <article-title>Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report</article-title>. <source>J Crohns Colitis</source> (<year>2014</year>) <volume>8</volume>:<fpage>1464</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1016/j.crohns.2014.05.010</pub-id><?supplied-pmid 24958064?><pub-id pub-id-type="pmid">24958064</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S-L</given-names></name><name><surname>Wang</surname><given-names>ZR</given-names></name><name><surname>Yang</surname><given-names>CQ</given-names></name></person-group>. <article-title>Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease</article-title>. <source>Exp Ther Med</source> (<year>2012</year>) <volume>4</volume>:<fpage>1051</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.3892/etm.2012.718</pub-id><?supplied-pmid 23226773?><pub-id pub-id-type="pmid">23226773</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahimi</surname><given-names>R</given-names></name><name><surname>Nikfar</surname><given-names>S</given-names></name><name><surname>Rezaie</surname><given-names>A</given-names></name><name><surname>Abdollahi</surname><given-names>M</given-names></name></person-group>. <article-title>A meta-analysis of antibiotic therapy for active ulcerative colitis</article-title>. <source>Dig Dis Sci</source> (<year>2007</year>) <volume>52</volume>:<fpage>2920</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1007/s10620-007-9760-1</pub-id><?supplied-pmid 17415632?><pub-id pub-id-type="pmid">17415632</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>KJ</given-names></name><name><surname>Ullman</surname><given-names>TA</given-names></name><name><surname>Ford</surname><given-names>AC</given-names></name><name><surname>Abreu</surname><given-names>MT</given-names></name><name><surname>Abadir</surname><given-names>A</given-names></name><name><surname>Marshall</surname><given-names>JK</given-names></name><etal/></person-group>
<article-title>Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis</article-title>. <source>Am J Gastroenterol</source> (<year>2011</year>) <volume>106</volume>:<fpage>661</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1038/ajg.2011.72</pub-id><?supplied-pmid 21407187?><pub-id pub-id-type="pmid">21407187</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McPhee</surname><given-names>JB</given-names></name><name><surname>Small</surname><given-names>CL</given-names></name><name><surname>Reid-Yu</surname><given-names>SA</given-names></name><name><surname>Brannon</surname><given-names>JR</given-names></name><name><surname>Le Moual</surname><given-names>H</given-names></name><name><surname>Coombes</surname><given-names>BK</given-names></name></person-group>
<article-title>Host defense peptide resistance contributes to colonization and maximal intestinal pathology by Crohn&#x02019;s disease-associated adherent-invasive <italic>Escherichia coli</italic></article-title>. <source>Infect Immun</source> (<year>2014</year>) <volume>82</volume>:<fpage>3383</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.01888-14</pub-id><pub-id pub-id-type="pmid">24866805</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Nusrat</surname><given-names>A</given-names></name><name><surname>Klapproth</surname><given-names>JM</given-names></name></person-group>
<article-title>Crohn&#x02019;s disease&#x02013;associated <italic>Escherichia coli</italic> survive in macrophages by suppressing NF&#x003ba;B signaling</article-title>. <source>Inflamm Bowel Dis</source> (<year>2014</year>) <volume>20</volume>:<fpage>1419</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1097/MIB.0000000000000096</pub-id><pub-id pub-id-type="pmid">24918323</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papamichael</surname><given-names>KX</given-names></name><name><surname>Papaioannou</surname><given-names>G</given-names></name><name><surname>Karga</surname><given-names>H</given-names></name><name><surname>Roussos</surname><given-names>A</given-names></name><name><surname>Mantzaris</surname><given-names>GJ</given-names></name></person-group>. <article-title><italic>Helicobacter pylori</italic> infection and endocrine disorders: is there a link?</article-title>
<source>World J Gastroenterol</source> (<year>2009</year>) <volume>15</volume>(<issue>22</issue>):<fpage>2701</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.3748/wjg.15.2701</pub-id><?supplied-pmid 19522019?><pub-id pub-id-type="pmid">19522019</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feller</surname><given-names>M</given-names></name><name><surname>Huwiler</surname><given-names>K</given-names></name><name><surname>Stephan</surname><given-names>R</given-names></name><name><surname>Altpeter</surname><given-names>E</given-names></name><name><surname>Shang</surname><given-names>A</given-names></name><name><surname>Furrer</surname><given-names>H</given-names></name><etal/></person-group>
<article-title><italic>Mycobacterium avium</italic> subspecies paratuberculosis and Crohn&#x02019;s disease: a systematic review and meta-analysis</article-title>. <source>Lancet Infect Dis</source> (<year>2007</year>) <volume>7</volume>:<fpage>607</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1016/S1473-3099(07)70211-6</pub-id><pub-id pub-id-type="pmid">17714674</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosca-Watts</surname><given-names>MM</given-names></name></person-group>
<article-title>Pathogenesis of Crohn&#x02019;s disease: bug or no bug</article-title>. <source>World J Gastrointest Pathophysiol</source> (<year>2015</year>) <volume>6</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.4291/wjgp.v6.i1.1</pub-id><pub-id pub-id-type="pmid">25685606</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>RL</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Tsolis</surname><given-names>RM</given-names></name><name><surname>Kingsley</surname><given-names>RA</given-names></name><name><surname>Adams</surname><given-names>LG</given-names></name><name><surname>B&#x000e4;umler</surname><given-names>AJ</given-names></name></person-group>. <article-title>Animal models of <italic>Salmonella</italic> infections: enteritis versus typhoid fever</article-title>. <source>Microbes Infect</source> (<year>2001</year>) <volume>3</volume>:<fpage>1335</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1016/S1286-4579(01)01495-2</pub-id><?supplied-pmid 11755423?><pub-id pub-id-type="pmid">11755423</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcus</surname><given-names>SL</given-names></name><name><surname>Brumell</surname><given-names>JH</given-names></name><name><surname>Pfeifer</surname><given-names>CG</given-names></name><name><surname>Finlay</surname><given-names>BB</given-names></name></person-group>. <article-title><italic>Salmonella</italic> pathogenicity islands: big virulence in small packages</article-title>. <source>Microbes Infect</source> (<year>2000</year>) <volume>2</volume>:<fpage>145</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="doi">10.1016/S1286-4579(00)00273-2</pub-id><?supplied-pmid 10742687?><pub-id pub-id-type="pmid">10742687</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galan</surname><given-names>JE</given-names></name></person-group>. <article-title><italic>Salmonella</italic> interactions with host cells: type III secretion at work</article-title>. <source>Biology (Basel)</source> (<year>2001</year>) <volume>17</volume>:<fpage>53</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.cellbio.17.1.53</pub-id><?supplied-pmid 11687484?><pub-id pub-id-type="pmid">11687484</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyrova</surname><given-names>K</given-names></name><name><surname>Stepanova</surname><given-names>H</given-names></name><name><surname>Rychlik</surname><given-names>I</given-names></name><name><surname>Faldyna</surname><given-names>M</given-names></name><name><surname>Volf</surname><given-names>J</given-names></name></person-group>. <article-title>SPI-1 encoded genes of <italic>Salmonella</italic> Typhimurium influence differential polarization of porcine alveolar macrophages in vitro</article-title>. <source>BMC Vet Res</source> (<year>2012</year>) <volume>8</volume>:<fpage>115</fpage>.<pub-id pub-id-type="doi">10.1186/1746-6148-8-115</pub-id><?supplied-pmid 22817641?><pub-id pub-id-type="pmid">22817641</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hensel</surname><given-names>M</given-names></name></person-group>. <article-title>Evolution of pathogenicity islands of <italic>Salmonella enterica</italic></article-title>. <source>Int J Med Microbiol</source> (<year>2004</year>) <volume>294</volume>:<fpage>95</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="doi">10.1016/j.ijmm.2004.06.025</pub-id><?supplied-pmid 15493819?><pub-id pub-id-type="pmid">15493819</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broz</surname><given-names>P</given-names></name><name><surname>Ohlson</surname><given-names>MB</given-names></name><name><surname>Monack</surname><given-names>DM</given-names></name></person-group>. <article-title>Innate immune response to <italic>Salmonella typhimurium</italic>, a model enteric pathogen</article-title>. <source>Gut Microbes</source> (<year>2012</year>) <volume>3</volume>:<fpage>62</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="doi">10.4161/gmic.19141</pub-id><?supplied-pmid 22198618?><pub-id pub-id-type="pmid">22198618</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>CM</given-names></name></person-group>. <article-title>The dynamic interactions between <italic>Salmonella</italic> and the microbiota, within the challenging niche of the gastrointestinal tract</article-title>. <source>Int Sch Res Notices</source> (<year>2014</year>) <volume>2014</volume>:<fpage>846049</fpage>.<pub-id pub-id-type="doi">10.1155/2014/846049</pub-id><?supplied-pmid 27437481?><pub-id pub-id-type="pmid">27437481</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f6;hler</surname><given-names>H</given-names></name><name><surname>Sakaguchi</surname><given-names>T</given-names></name><name><surname>Hurley</surname><given-names>BP</given-names></name><name><surname>Kase</surname><given-names>BA</given-names></name><name><surname>Reinecker</surname><given-names>HC</given-names></name><name><surname>McCormick</surname><given-names>BA</given-names></name></person-group>. <article-title><italic>Salmonella enterica</italic> serovar Typhimurium regulates intercellular junction proteins and facilitates transepithelial neutrophil and bacterial passage</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source> (<year>2007</year>) <volume>293</volume>(<issue>1</issue>):<fpage>G178</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="doi">10.1152/ajpgi.00535.2006</pub-id><?supplied-pmid 17615177?><pub-id pub-id-type="pmid">17615177</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niess</surname><given-names>JH</given-names></name><name><surname>Brand</surname><given-names>S</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Landsman</surname><given-names>L</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>McCormick</surname><given-names>BA</given-names></name><etal/></person-group>
<article-title>CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance</article-title>. <source>Science</source> (<year>2005</year>) <volume>307</volume>:<fpage>254</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1126/science.1102901</pub-id><?supplied-pmid 15653504?><pub-id pub-id-type="pmid">15653504</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vazquez-Torres</surname><given-names>A</given-names></name><name><surname>Jones-Carson</surname><given-names>J</given-names></name><name><surname>B&#x000e4;umler</surname><given-names>AJ</given-names></name><name><surname>Falkow</surname><given-names>S</given-names></name><name><surname>Valdivia</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Extraintestinal dissemination of <italic>Salmonella</italic> by CD18-expressing phagocytes</article-title>. <source>Nature</source> (<year>1999</year>) <volume>401</volume>:<fpage>804</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/44593</pub-id><?supplied-pmid 10548107?><pub-id pub-id-type="pmid">10548107</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moest</surname><given-names>TP</given-names></name><name><surname>M&#x000e9;resse</surname><given-names>S</given-names></name></person-group>. <article-title><italic>Salmonella</italic> T3SSs: successful mission of the secret(ion) agents</article-title>. <source>Curr Opin Microbiol</source> (<year>2013</year>) <volume>16</volume>:<fpage>38</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1016/j.mib.2012.11.006</pub-id><?supplied-pmid 23295139?><pub-id pub-id-type="pmid">23295139</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>McCormick</surname><given-names>B</given-names></name></person-group>. <article-title>Mucosal inflammatory response to <italic>Salmonella typhimurium</italic> infection</article-title>. <source>Front Immunol</source> (<year>2014</year>) <volume>5</volume>:<fpage>311</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2014.00311</pub-id><?supplied-pmid 25071772?><pub-id pub-id-type="pmid">25071772</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>AP</given-names></name><name><surname>Petrof</surname><given-names>EO</given-names></name><name><surname>Kuppireddi</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Claud</surname><given-names>EC</given-names></name><etal/></person-group>
<article-title><italic>Salmonella</italic> type III effector AvrA stabilizes cell tight junctions to inhibit inflammation in intestinal epithelial cells</article-title>. <source>PLoS One</source> (<year>2008</year>) <volume>3</volume>:<fpage>e2369</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0002369</pub-id><?supplied-pmid 18523661?><pub-id pub-id-type="pmid">18523661</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Petrof</surname><given-names>EO</given-names></name><name><surname>Boone</surname><given-names>D</given-names></name><name><surname>Claud</surname><given-names>EC</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name></person-group>. <article-title><italic>Salmonella</italic> effector AvrA regulation of colonic epithelial cell inflammation by deubiquitination</article-title>. <source>Am J Pathol</source> (<year>2007</year>) <volume>171</volume>:<fpage>882</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.2353/ajpath.2007.070220</pub-id><?supplied-pmid 17690189?><pub-id pub-id-type="pmid">17690189</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>RM</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Wentworth</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Collier-Hyams</surname><given-names>L</given-names></name><name><surname>Neish</surname><given-names>AS</given-names></name></person-group>. <article-title><italic>Salmonella</italic> AvrA coordinates suppression of host immune and apoptotic defenses via JNK pathway blockade</article-title>. <source>Cell Host Microbe</source> (<year>2008</year>) <volume>3</volume>:<fpage>233</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1016/j.chom.2008.02.016</pub-id><?supplied-pmid 18407067?><pub-id pub-id-type="pmid">18407067</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monack</surname><given-names>DM</given-names></name><name><surname>Hersh</surname><given-names>D</given-names></name><name><surname>Ghori</surname><given-names>N</given-names></name><name><surname>Bouley</surname><given-names>D</given-names></name><name><surname>Zychlinsky</surname><given-names>A</given-names></name><name><surname>Falkow</surname><given-names>S</given-names></name></person-group>
<article-title><italic>Salmonella</italic> exploits caspase-1 to colonize Peyer&#x02019;s patches in a murine typhoid model</article-title>. <source>J Exp Med</source> (<year>2000</year>) <volume>192</volume>:<fpage>249</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="doi">10.1084/jem.192.2.249</pub-id><pub-id pub-id-type="pmid">10899911</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariathasan</surname><given-names>S</given-names></name><name><surname>Newton</surname><given-names>K</given-names></name><name><surname>Monack</surname><given-names>DM</given-names></name><name><surname>Vucic</surname><given-names>D</given-names></name><name><surname>French</surname><given-names>DM</given-names></name><name><surname>Lee</surname><given-names>WP</given-names></name><etal/></person-group>
<article-title>Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf</article-title>. <source>Nature</source> (<year>2004</year>) <volume>430</volume>:<fpage>213</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/nature02664</pub-id><?supplied-pmid 15190255?><pub-id pub-id-type="pmid">15190255</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolli</surname><given-names>J</given-names></name><name><surname>Loukili</surname><given-names>N</given-names></name><name><surname>Levrand</surname><given-names>S</given-names></name><name><surname>Rosenblatt-Velin</surname><given-names>N</given-names></name><name><surname>Rignault-Clerc</surname><given-names>S</given-names></name><name><surname>Waeber</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Bacterial flagellin elicits widespread innate immune defense mechanisms, apoptotic signaling, and a sepsis-like systemic inflammatory response in mice</article-title>. <source>Crit Care</source> (<year>2010</year>) <volume>14</volume>:<fpage>R160</fpage>.<pub-id pub-id-type="doi">10.1186/cc9235</pub-id><?supplied-pmid 20731882?><pub-id pub-id-type="pmid">20731882</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Lyons</surname><given-names>S</given-names></name><name><surname>Carlson</surname><given-names>A</given-names></name><name><surname>Merlin</surname><given-names>D</given-names></name><name><surname>Neish</surname><given-names>AS</given-names></name><etal/></person-group>
<article-title>TLR5-mediated activation of p38 MAPK regulates epithelial IL-8 expression via posttranscriptional mechanism</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source> (<year>2003</year>) <volume>285</volume>:<fpage>G282</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1152/ajpgi.00503.2002</pub-id><?supplied-pmid 12702497?><pub-id pub-id-type="pmid">12702497</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bueno</surname><given-names>SM</given-names></name><name><surname>Riquelme</surname><given-names>S</given-names></name><name><surname>Riedel</surname><given-names>CA</given-names></name><name><surname>Kalergis</surname><given-names>AM</given-names></name></person-group>. <article-title>Mechanisms used by virulent <italic>Salmonella</italic> to impair dendritic cell function and evade adaptive immunity</article-title>. <source>Immunology</source> (<year>2012</year>) <volume>137</volume>:<fpage>28</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2567.2012.03614.x</pub-id><?supplied-pmid 22703384?><pub-id pub-id-type="pmid">22703384</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geddes</surname><given-names>K</given-names></name><name><surname>Rubino</surname><given-names>S</given-names></name><name><surname>Streutker</surname><given-names>C</given-names></name><name><surname>Cho</surname><given-names>JH</given-names></name><name><surname>Magalhaes</surname><given-names>JG</given-names></name><name><surname>Le Bourhis</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Nod1 and Nod2 regulation of inflammation in the <italic>Salmonella</italic> colitis model</article-title>. <source>Infect Immun</source> (<year>2010</year>) <volume>78</volume>:<fpage>5107</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.00759-10</pub-id><?supplied-pmid 20921147?><pub-id pub-id-type="pmid">20921147</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreira</surname><given-names>LO</given-names></name><name><surname>Zamboni</surname><given-names>DS</given-names></name></person-group>. <article-title>NOD1 and NOD2 signaling in infection and inflammation</article-title>. <source>Front Immunol</source> (<year>2012</year>) <volume>8</volume>(<issue>3</issue>):<fpage>328</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2012.00328</pub-id><?supplied-pmid 23162548?><pub-id pub-id-type="pmid">23162548</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Travassos</surname><given-names>LH</given-names></name><name><surname>Carneiro</surname><given-names>LA</given-names></name><name><surname>Ramjeet</surname><given-names>M</given-names></name><name><surname>Hussey</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>YG</given-names></name><name><surname>Magalh&#x000e3;es</surname><given-names>JG</given-names></name><etal/></person-group>
<article-title>Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry: commentary</article-title>. <source>Nat Rev Immunol</source> (<year>2010</year>) <volume>11</volume>:<fpage>55</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1038/ni.1823</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawhon</surname><given-names>SD</given-names></name><name><surname>Maurer</surname><given-names>R</given-names></name><name><surname>Suyemoto</surname><given-names>M</given-names></name><name><surname>Altier</surname><given-names>C</given-names></name></person-group>. <article-title>Intestinal short-chain fatty acids alter <italic>Salmonella</italic> Typhimurium invasion gene expression and virulence through BarA/SirA</article-title>. <source>Mol Microbiol</source> (<year>2002</year>) <volume>46</volume>(<issue>5</issue>):<fpage>1451</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1046/j.1365-2958.2002.03268.x</pub-id><?supplied-pmid 12453229?><pub-id pub-id-type="pmid">12453229</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gantois</surname><given-names>I</given-names></name><name><surname>Ducatelle</surname><given-names>R</given-names></name><name><surname>Pasmans</surname><given-names>F</given-names></name><name><surname>Haesebrouck</surname><given-names>F</given-names></name><name><surname>Hautefort</surname><given-names>I</given-names></name><name><surname>Thompson</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Butyrate specifically down-regulates <italic>Salmonella</italic> pathogenicity island 1 gene expression</article-title>. <source>Appl Environ Microbiol</source> (<year>2006</year>) <volume>72</volume>(<issue>1</issue>):<fpage>946</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1128/AEM.72.1.946</pub-id><?supplied-pmid 16391141?><pub-id pub-id-type="pmid">16391141</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>CC</given-names></name><name><surname>Garner</surname><given-names>CD</given-names></name><name><surname>Slauch</surname><given-names>JM</given-names></name><name><surname>Dwyer</surname><given-names>ZW</given-names></name><name><surname>Lawhon</surname><given-names>SD</given-names></name><name><surname>Frye</surname><given-names>JG</given-names></name><etal/></person-group>
<article-title>The intestinal fatty acid propionate inhibits <italic>Salmonella</italic> invasion through the post-translational control of HilD</article-title>. <source>Mol Microbiol</source> (<year>2013</year>) <volume>87</volume>:<fpage>1045</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1111/mmi.12149</pub-id><?supplied-pmid 23289537?><pub-id pub-id-type="pmid">23289537</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiennimitr</surname><given-names>P</given-names></name><name><surname>Winter</surname><given-names>SE</given-names></name><name><surname>Winter</surname><given-names>MG</given-names></name><name><surname>Xavier</surname><given-names>MN</given-names></name><name><surname>Tolstikov</surname><given-names>V</given-names></name><name><surname>Huseby</surname><given-names>DL</given-names></name><etal/></person-group>
<article-title>From the cover: intestinal inflammation allows <italic>Salmonella</italic> to use ethanolamine to compete with the microbiota</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2011</year>) <volume>108</volume>:<fpage>17480</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1107857108</pub-id><pub-id pub-id-type="pmid">21969563</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>SE</given-names></name><name><surname>Thiennimitr</surname><given-names>P</given-names></name><name><surname>Winter</surname><given-names>MG</given-names></name><name><surname>Butler</surname><given-names>BP</given-names></name><name><surname>Huseby</surname><given-names>DL</given-names></name><name><surname>Crawford</surname><given-names>RW</given-names></name><etal/></person-group>
<article-title>Gut inflammation provides a respiratory electron acceptor for <italic>Salmonella</italic></article-title>. <source>Nature</source> (<year>2010</year>) <volume>467</volume>:<fpage>426</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/nature09415</pub-id><?supplied-pmid 20864996?><pub-id pub-id-type="pmid">20864996</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiennimitr</surname><given-names>P</given-names></name><name><surname>Winter</surname><given-names>SE</given-names></name><name><surname>B&#x000e4;umler</surname><given-names>AJ</given-names></name></person-group>. <article-title><italic>Salmonella</italic>, the host and its microbiota</article-title>. <source>Curr Opin Microbiol</source> (<year>2012</year>) <volume>15</volume>:<fpage>108</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1016/j.mib.2011.10.002</pub-id><?supplied-pmid 22030447?><pub-id pub-id-type="pmid">22030447</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>N</given-names></name><name><surname>Ferreira</surname><given-names>RB</given-names></name><name><surname>Antunes</surname><given-names>LC</given-names></name><name><surname>Willing</surname><given-names>BP</given-names></name><name><surname>Sekirov</surname><given-names>I</given-names></name><name><surname>Al-Zahrani</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Neutrophil elastase alters the murine gut microbiota resulting in enhanced <italic>Salmonella</italic> colonization</article-title>. <source>PLoS One</source> (<year>2012</year>) <volume>7</volume>:<fpage>e49646</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0049646</pub-id><?supplied-pmid 23155475?><pub-id pub-id-type="pmid">23155475</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sartor</surname><given-names>RB</given-names></name></person-group>. <article-title>Microbial influences in inflammatory bowel diseases</article-title>. <source>Gastroenterology</source> (<year>2008</year>) <volume>134</volume>:<fpage>577</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1053/j.gastro.2007.11.059</pub-id><?supplied-pmid 18242222?><pub-id pub-id-type="pmid">18242222</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group>. <article-title>Serum bacterial toxins are related to the progression of inflammatory bowel disease</article-title>. <source>Scand J Gastroenterol</source> (<year>2014</year>) <volume>49</volume>:<fpage>826</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.3109/00365521.2014.919018</pub-id><?supplied-pmid 24853095?><pub-id pub-id-type="pmid">24853095</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jess</surname><given-names>T</given-names></name><name><surname>Simonsen</surname><given-names>J</given-names></name><name><surname>Nielsen</surname><given-names>NM</given-names></name><name><surname>J&#x000f8;rgensen</surname><given-names>KT</given-names></name><name><surname>Bager</surname><given-names>P</given-names></name><name><surname>Ethelberg</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Enteric <italic>Salmonella</italic> or <italic>Campylobacter</italic> infections and the risk of inflammatory bowel disease</article-title>. <source>Gut</source> (<year>2011</year>) <volume>60</volume>:<fpage>318</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1136/gut.2010.223396</pub-id><pub-id pub-id-type="pmid">21193449</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez-Lobos</surname><given-names>M</given-names></name><name><surname>Pizarro</surname><given-names>DP</given-names></name><name><surname>Palavecino</surname><given-names>CE</given-names></name><name><surname>Espinoza</surname><given-names>A</given-names></name><name><surname>Sebasti&#x000e1;n</surname><given-names>VP</given-names></name><name><surname>Alvarado</surname><given-names>JC</given-names></name><etal/></person-group>
<article-title>Role of <italic>Salmonella enterica</italic> exposure in Chilean Crohn&#x02019;s disease patients</article-title>. <source>World J Gastroenterol</source> (<year>2013</year>) <volume>19</volume>:<fpage>5855</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.3748/wjg.v19.i35.5855</pub-id><pub-id pub-id-type="pmid">24124330</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stecher</surname><given-names>B</given-names></name><name><surname>Chaffron</surname><given-names>S</given-names></name><name><surname>K&#x000e4;ppeli</surname><given-names>R</given-names></name><name><surname>Hapfelmeier</surname><given-names>S</given-names></name><name><surname>Freedrich</surname><given-names>S</given-names></name><name><surname>Weber</surname><given-names>TC</given-names></name><etal/></person-group>
<article-title>Like will to like: abundances of closely related species can predict susceptibility to intestinal colonization by pathogenic and commensal bacteria</article-title>. <source>PLoS Pathog</source> (<year>2010</year>) <volume>6</volume>(<issue>1</issue>):<fpage>e1000711</fpage>.<pub-id pub-id-type="doi">10.1371/journal.ppat.1000711</pub-id><?supplied-pmid 20062525?><pub-id pub-id-type="pmid">20062525</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honko</surname><given-names>AN</given-names></name><name><surname>Mizel</surname><given-names>SB</given-names></name></person-group>. <article-title>Effects of flagellin on innate and adaptive immunity</article-title>. <source>Immunol Res</source> (<year>2005</year>) <volume>33</volume>:<fpage>83</fpage>&#x02013;<lpage>101</lpage>.<pub-id pub-id-type="doi">10.1385/IR:33:1:083</pub-id><?supplied-pmid 16120974?><pub-id pub-id-type="pmid">16120974</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roggenbuck</surname><given-names>D</given-names></name><name><surname>Hausdorf</surname><given-names>G</given-names></name><name><surname>Martinez-Gamboa</surname><given-names>L</given-names></name><name><surname>Reinhold</surname><given-names>D</given-names></name><name><surname>B&#x000fc;ttner</surname><given-names>T</given-names></name><name><surname>Jungblut</surname><given-names>PR</given-names></name><etal/></person-group>
<article-title>Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn&#x02019;s disease</article-title>. <source>Gut</source> (<year>2009</year>) <volume>58</volume>:<fpage>1620</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1136/gut.2008.162495</pub-id><pub-id pub-id-type="pmid">19549613</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaishnava</surname><given-names>S</given-names></name><name><surname>Behrendt</surname><given-names>CL</given-names></name><name><surname>Ismail</surname><given-names>AS</given-names></name><name><surname>Eckmann</surname><given-names>L</given-names></name><name><surname>Hooper</surname><given-names>LV</given-names></name></person-group>. <article-title>Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2008</year>) <volume>105</volume>:<fpage>20858</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0808723105</pub-id><?supplied-pmid 19075245?><pub-id pub-id-type="pmid">19075245</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wehkamp</surname><given-names>J</given-names></name></person-group>
<article-title>Reduced Paneth cell alphadefensins in ileal Crohn&#x02019;s disease</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2005</year>) <volume>102</volume>:<fpage>18129</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0505256102</pub-id><pub-id pub-id-type="pmid">16330776</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salzman</surname><given-names>NH</given-names></name><name><surname>Chou</surname><given-names>MM</given-names></name><name><surname>de Jong</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Porter</surname><given-names>EM</given-names></name><name><surname>Paterson</surname><given-names>Y</given-names></name></person-group>. <article-title>Enteric <italic>Salmonella</italic> infection inhibits Paneth cell antimicrobial peptide expression</article-title>. <source>Infect Immun</source> (<year>2003</year>) <volume>71</volume>(<issue>3</issue>):<fpage>1109</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.71.3.1109</pub-id><?supplied-pmid 12595421?><pub-id pub-id-type="pmid">12595421</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begun</surname><given-names>J</given-names></name><name><surname>Lassen</surname><given-names>KG</given-names></name><name><surname>Jijon</surname><given-names>HB</given-names></name><name><surname>Baxt</surname><given-names>LA</given-names></name><name><surname>Goel</surname><given-names>G</given-names></name><name><surname>Heath</surname><given-names>RJ</given-names></name><etal/></person-group>
<article-title>Integrated genomics of Crohn&#x02019;s disease risk variant identifies a role for CLEC12A in antibacterial autophagy</article-title>. <source>Cell Rep</source> (<year>2015</year>) <volume>11</volume>:<fpage>1905</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="doi">10.1016/j.celrep.2015.05.045</pub-id><pub-id pub-id-type="pmid">26095365</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez Rodriguez</surname><given-names>NR</given-names></name><name><surname>Eloi</surname><given-names>MD</given-names></name><name><surname>Huynh</surname><given-names>A</given-names></name><name><surname>Dominguez</surname><given-names>T</given-names></name><name><surname>Lam</surname><given-names>AH</given-names></name><name><surname>Carcamo-Molina</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Expansion of Paneth cell population in response to enteric <italic>Salmonella enterica</italic> serovar Typhimurium infection</article-title>. <source>Infect Immun</source> (<year>2012</year>) <volume>80</volume>:<fpage>266</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.05638-11</pub-id><?supplied-pmid 22006567?><pub-id pub-id-type="pmid">22006567</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gersemann</surname><given-names>M</given-names></name><name><surname>Stange</surname><given-names>EF</given-names></name><name><surname>Wehkamp</surname><given-names>J</given-names></name></person-group>. <article-title>From intestinal stem cells to inflammatory bowel diseases</article-title>. <source>World J Gastroenterol</source> (<year>2011</year>) <volume>17</volume>:<fpage>3198</fpage>&#x02013;<lpage>203</lpage>.<pub-id pub-id-type="doi">10.3748/wjg.v17.i27.3198</pub-id><?supplied-pmid 21912468?><pub-id pub-id-type="pmid">21912468</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conway</surname><given-names>KL</given-names></name><name><surname>Kuballa</surname><given-names>P</given-names></name><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Patel</surname><given-names>KK</given-names></name><name><surname>Castoreno</surname><given-names>AB</given-names></name><name><surname>Yilmaz</surname><given-names>OH</given-names></name><etal/></person-group>
<article-title>Atg16l1 is required for autophagy in intestinal epithelial cells and protection of mice from <italic>Salmonella</italic> infection</article-title>. <source>Gastroenterology</source> (<year>2013</year>) <volume>145</volume>:<fpage>1347</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1053/j.gastro.2013.08.035</pub-id><?supplied-pmid 23973919?><pub-id pub-id-type="pmid">23973919</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>LC</given-names></name><name><surname>Dikic</surname><given-names>I</given-names></name></person-group>. <article-title>Autophagy in antimicrobial immunity</article-title>. <source>Mol Cell</source> (<year>2014</year>) <volume>54</volume>:<fpage>224</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1016/j.molcel.2014.03.009</pub-id><?supplied-pmid 24766886?><pub-id pub-id-type="pmid">24766886</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuballa</surname><given-names>P</given-names></name><name><surname>Huett</surname><given-names>A</given-names></name><name><surname>Rioux</surname><given-names>JD</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name></person-group>
<article-title>Impaired autophagy of an intracellular pathogen induced by a Crohn&#x02019;s disease associated ATG16L1 variant</article-title>. <source>PLoS One</source> (<year>2008</year>) <volume>3</volume>(<issue>10</issue>):<fpage>e3391</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0003391</pub-id><pub-id pub-id-type="pmid">18852889</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homer</surname><given-names>CR</given-names></name><name><surname>Richmond</surname><given-names>AL</given-names></name><name><surname>Rebert</surname><given-names>NA</given-names></name><name><surname>Achkar</surname><given-names>JP</given-names></name><name><surname>McDonald</surname><given-names>C</given-names></name></person-group>
<article-title>ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn&#x02019;s disease pathogenesis</article-title>. <source>Gastroenterology</source> (<year>2010</year>) <volume>139</volume>:<fpage>1630</fpage>&#x02013;<lpage>41.e2</lpage>.<pub-id pub-id-type="doi">10.1053/j.gastro.2010.07.006</pub-id><pub-id pub-id-type="pmid">20637199</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooney</surname><given-names>R</given-names></name><name><surname>Baker</surname><given-names>J</given-names></name><name><surname>Brain</surname><given-names>O</given-names></name><name><surname>Danis</surname><given-names>B</given-names></name><name><surname>Pichulik</surname><given-names>T</given-names></name><name><surname>Allan</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation</article-title>. <source>Nat Med</source> (<year>2010</year>) <volume>16</volume>:<fpage>90</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1038/nm.2069</pub-id><?supplied-pmid 19966812?><pub-id pub-id-type="pmid">19966812</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bueno</surname><given-names>SM</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>PA</given-names></name><name><surname>Carre&#x000f1;o</surname><given-names>LJ</given-names></name><name><surname>Tobar</surname><given-names>JA</given-names></name><name><surname>Mora</surname><given-names>GC</given-names></name><name><surname>Pereda</surname><given-names>CJ</given-names></name><etal/></person-group>
<article-title>The capacity of <italic>Salmonella</italic> to survive inside dendritic cells and prevent antigen presentation to T cells is host specific</article-title>. <source>Immunology</source> (<year>2008</year>) <volume>124</volume>:<fpage>522</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2567.2008.02805.x</pub-id><?supplied-pmid 18266715?><pub-id pub-id-type="pmid">18266715</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voedisch</surname><given-names>S</given-names></name><name><surname>Koenecke</surname><given-names>C</given-names></name><name><surname>David</surname><given-names>S</given-names></name><name><surname>Herbrand</surname><given-names>H</given-names></name><name><surname>F&#x000f6;rster</surname><given-names>R</given-names></name><name><surname>Rhen</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Mesenteric lymph nodes confine dendritic cell-mediated dissemination of <italic>Salmonella enterica</italic> serovar Typhimurium and limit systemic disease in mice</article-title>. <source>Infect Immun</source> (<year>2009</year>) <volume>77</volume>:<fpage>3170</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.00272-09</pub-id><?supplied-pmid 19506012?><pub-id pub-id-type="pmid">19506012</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godinez</surname><given-names>I</given-names></name><name><surname>Raffatellu</surname><given-names>M</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>Paix&#x000e3;o</surname><given-names>TA</given-names></name><name><surname>Haneda</surname><given-names>T</given-names></name><name><surname>Santos</surname><given-names>RL</given-names></name><etal/></person-group>
<article-title>Interleukin-23 orchestrates mucosal responses to <italic>Salmonella enterica</italic> serotype Typhimurium in the intestine</article-title>. <source>Infect Immun</source> (<year>2009</year>) <volume>77</volume>:<fpage>387</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.00933-08</pub-id><?supplied-pmid 18955477?><pub-id pub-id-type="pmid">18955477</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coburn</surname><given-names>B</given-names></name><name><surname>Grassl</surname><given-names>GA</given-names></name><name><surname>Finlay</surname><given-names>BB</given-names></name></person-group>. <article-title><italic>Salmonella</italic>, the host and disease: a brief review</article-title>. <source>Immunol Cell Biol</source> (<year>2007</year>) <volume>85</volume>:<fpage>112</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/sj.icb.7100007</pub-id><?supplied-pmid 17146467?><pub-id pub-id-type="pmid">17146467</pub-id></mixed-citation></ref></ref-list></back></article>